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Carbohydrate	  and	  lipid	  metabolism	  encompass	  a	  complex	  network	  of	  pathways	  that	  maintain	  proper	  energy	  homeostasis.	  	  In	  regards	  to	  the	  consumption	  of	  carbohydrates,	  the	  process	  of	  lipogenesis	  is	  involved	  in	  converting	  excess	  glucose	  molecules	  into	  energy-­‐storing	  molecules	  known	  as	  triacylglycerides.	  In	  response	  to	  nutrient	  and	  hormone	  signals,	  the	  expression	  of	  the	  enzymes	  involved	  in	  lipogenesis	  is	  highly	  regulated	  to	  allow	  for	  increases	  or	  decreases	  in	  lipogenesis.	  The	  lipogenic	  enzymes	  include	  malic	  enzyme,	  fatty	  acid	  synthase,	  ATP-­‐citrate	  lysase,	  acetyl-­‐CoA	  carboxylase	  and	  glucose-­‐6-­‐phosphate	  dehydrogenase	  (G6PD).	  The	  expression	  of	  these	  enzymes	  increases	  following	  the	  consumption	  of	  a	  high	  carbohydrate	  meal	  and	  decreases	  in	  response	  to	  starvation	  (1).	  Our	  laboratory	  is	  interested	  in	  how	  hormones	  like	  insulin	  and	  glucagon,	  as	  well	  as	  dietary	  nutrients,	  like	  fatty	  acids,	  regulate	  the	  expression	  of	  these	  enzymes.	  To	  approach	  the	  cellular	  mechanisms	  involved	  in	  nutrient	  regulation	  of	  gene	  expression,	  we	  have	  used	  G6PD	  as	  our	  model	  gene.	  	  
	   In	  order	  to	  study	  the	  effects	  of	  nutrients	  on	  the	  expression	  of	  G6PD,	  we	  use	  refeeding	  after	  a	  period	  of	  starvation	  and	  starvation	  alone	  as	  the	  dietary	  paradigms.	  Starvation	  causes	  a	  decrease	  in	  the	  G6PD	  activity	  and	  the	  expression	  of	  G6PD	  mRNA,	  while	  starvation	  that	  is	  followed	  by	  a	  period	  of	  refeeding	  results	  in	  a	  large	  increase	  in	  G6PD	  activity	  and	  expression	  of	  G6PD	  mRNA.	  Starvation	  followed	  by	  a	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period	  of	  refeeding	  causes	  a	  larger	  increase	  in	  G6PD	  activity	  and	  the	  expression	  of	  G6PD	  mRNA	  than	  animals	  fed	  ad	  libitum.	  This	  effect	  on	  G6PD	  activity	  by	  starvation	  followed	  by	  a	  period	  of	  refeeding	  is	  called	  enzyme	  overshoot	  (2,3)	  and	  the	  large	  changes	  in	  the	  expression	  of	  G6PD	  mRNA	  explain	  the	  changes	  in	  G6PD	  activity	  (3-­‐9).	  	  	  
Unlike	  the	  regulation	  of	  most	  lipogenic	  enzymes,	  which	  occurs	  through	  changes	  in	  the	  rate	  of	  transcription	  for	  their	  genes,	  our	  laboratory	  discovered	  that	  the	  change	  in	  the	  expression	  of	  G6PD	  is	  due	  to	  changes	  in	  the	  splicing	  of	  its	  mRNA	  (3,10-­‐13).	  Current	  research	  in	  our	  laboratory	  has	  focused	  on	  how	  the	  different	  dietary	  conditions	  cause	  changes	  in	  the	  splicing	  of	  G6PD	  mRNA.	  Starvation	  inhibits	  the	  expression	  of	  G6PD	  mRNA	  by	  causing	  a	  decrease	  in	  the	  splicing	  of	  the	  G6PD	  mRNA	  (3,10-­‐13).	  In	  addition,	  the	  heterogeneous	  nuclear	  ribonucleoproteins	  (hnRNPs)	  that	  include	  hnRNP	  K,	  hnRNP	  L,	  and	  hnRNP	  A2/B1	  may	  be	  necessary	  for	  the	  inhibition	  of	  the	  splicing	  of	  G6PD	  mRNA	  by	  starvation.	  In	  in	  vitro	  assays,	  these	  hnRNPs	  bind	  more	  to	  the	  G6PD	  mRNA	  during	  starvation	  then	  during	  refeeding	  (14).	  The	  nutrient	  signals	  during	  starvation	  may	  cause	  changes	  in	  the	  activity	  of	  these	  splicing	  factors	  that	  allows	  them	  to	  bind	  to	  the	  mRNA	  and	  inhibit	  splicing.	  	  
All	  mRNAs	  are	  spliced	  before	  they	  can	  be	  transcribed.	  Nutrient	  regulation	  of	  splicing	  is	  most	  likely	  not	  unique	  to	  G6PD.	  Reports	  indicate	  that	  greater	  than	  90%	  of	  our	  genes	  are	  alternatively	  spliced	  (15,16)	  and	  that	  the	  human	  genome	  contains	  around	  23,000	  genes	  but	  they	  encode	  for	  over	  90,000	  proteins	  (17,18).	  The	  increase	  in	  protein	  diversity	  occurs	  at	  least	  partly	  due	  to	  the	  ability	  of	  alternative	  splicing	  to	  include	  or	  exclude	  various	  exons	  within	  a	  transcript,	  which	  changes	  the	  final	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message	  that	  is	  to	  be	  translated.	  Thus,	  understanding	  how	  nutrients	  control	  this	  step	  in	  gene	  expression	  is	  important	  for	  elucidating	  all	  aspects	  by	  which	  nutritional	  status	  can	  regulate	  cellular	  function.	  	  In	  regards	  to	  the	  inhibition	  of	  the	  expression	  of	  G6PD	  mRNA	  by	  starvation,	  we	  hypothesize	  that	  splicing	  factors	  hnRNP	  K,	  hnRNP	  L,	  and/or	  hnRNP	  A2/B1	  are	  necessary	  for	  the	  inhibition	  of	  the	  splicing	  of	  G6PD	  mRNA	  during	  starvation.	  One	  function	  of	  the	  hnRNPs	  is	  the	  inhibition	  of	  RNA	  splicing.	  The	  enhanced	  binding	  of	  these	  hnRNPs	  to	  the	  G6PD	  mRNA	  occurs	  concurrently	  with	  the	  decrease	  in	  the	  splicing	  and	  expression	  of	  G6PD	  mRNA.	  	  	  	  
II.	  RNA	  Splicing	  




A.	  Types	  of	  Alternative	  splicing	  	  
	   A	  pre-­‐mRNA	  that	  contains	  multiple	  exons	  has	  the	  potential	  to	  produce	  multiple	  mRNAs	  from	  one	  pre-­‐mRNA.	  The	  exons	  that	  are	  always	  included	  in	  the	  final	  transcript	  are	  called	  constitutive	  exons.	  The	  splicing	  of	  certain	  exons	  that	  are	  not	  always	  included	  in	  the	  final	  transcript	  is	  typically	  regulated	  and	  are	  known	  as	  alternatively	  spliced	  exons.	  Depending	  on	  the	  removal	  or	  inclusion	  of	  an	  exon	  in	  the	  final	  transcript,	  the	  final	  mRNA	  can	  have	  an	  exon	  structure	  that	  varies	  greatly	  (Fig	  1).	  Intron	  retention	  occurs	  when	  RNA	  splicing	  is	  inhibited	  and	  an	  intron	  remains	  in	  the	  final	  mRNA.	  The	  retention	  of	  an	  intron	  can	  lead	  to	  the	  production	  of	  a	  protein	  with	  altered	  function	  or	  the	  retention	  of	  an	  intron	  can	  lead	  to	  degradation	  of	  the	  RNA	  due	  to	  the	  introduction	  of	  a	  premature	  stop	  codon.	  The	  RNA	  that	  contains	  a	  premature	  stop	  codon	  is	  degraded	  via	  the	  nonsense-­‐mediated	  decay	  pathway	  (19,20).	  	  Nonsense-­‐mediated	  decay	  surveys	  RNA	  for	  a	  premature	  stop	  codon	  to	  prevent	  the	  translation	  of	  these	  incorrect	  mRNAs	  into	  protein.	  The	  exonic	  inclusion/exclusion	  type	  of	  alternative	  splicing	  involves	  the	  inclusion	  or	  exclusion	  of	  a	  specific	  exon.	  The	  mutually	  exclusive	  type	  of	  alternative	  splicing	  also	  involves	  the	  inclusion	  or	  exclusion	  of	  certain	  exons	  in	  the	  final	  transcript;	  however,	  this	  type	  of	  alternative	  splicing	  occurs	  when	  the	  inclusion	  of	  one	  exon	  excludes	  another	  exon.	  The	  inclusion	  or	  exclusion	  of	  certain	  exons	  will	  ultimately	  alter	  the	  protein	  coding	  sequence.	  By	  including	  or	  excluding	  certain	  exons,	  the	  protein	  produced	  from	  that	  mRNA	  could	  differ	  greatly	  in	  protein	  structure	  and	  function.	  Certain	  alternatively	  spliced	  exons	  can	  code	  for	  whole	  domains	  of	  proteins.	  Lastly,	  the	  alternative	  5’	  or	  3’	  splice	  site	  selection	  will	  produce	  an	  exon	  of	  varying	  length	  depending	  on	  the	  site	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B.	  The	  Spliceosome	  
RNA	  splicing	  is	  mediated	  by	  a	  large	  macromolecular	  structure	  that	  is	  called	  the	  spliceosome.	  The	  spliceosome	  consists	  of	  small	  nuclear	  ribonucleoprotein	  complexes	  (snRNPs)	  and	  potentially	  over	  300	  other	  proteins	  that	  are	  involved	  in	  the	  splicing	  process	  (22).	  The	  main	  snRNPs	  are	  U1,	  U2,	  U4/U6,	  U5	  and	  they	  consist	  of	  protein	  and	  RNA.	  The	  RNA	  part	  of	  the	  snRNP	  is	  a	  small	  nuclear	  RNA	  (snRNA)	  and	  it	  is	  responsible	  for	  recognizing	  specific	  sequences	  within	  the	  introns	  of	  pre-­‐mRNA	  that	  are	  needed	  to	  define	  the	  exon/intron	  boundary.	  Also,	  the	  snRNPs	  contain	  proteins	  known	  as	  Sm	  and	  Lsm	  ring	  proteins	  that	  bind	  to	  the	  snRNA.	  The	  Sm	  and	  Lsm	  proteins	  are	  essential	  for	  proper	  spliceosome	  assembly	  and	  function.	  These	  proteins	  provide	  the	  protein-­‐protein	  interactions	  that	  occur	  throughout	  the	  RNA	  splicing	  process.	  	  In	  addition	  to	  the	  snRNPs,	  RNA	  splicing	  involves	  proteins	  that	  enhance	  or	  inhibit	  splicing	  by	  binding	  to	  specific	  sequences	  found	  in	  the	  pre-­‐mRNA.	  The	  proteins	  that	  enhance	  splicing	  are	  the	  serine-­‐arginine	  rich	  (SR)	  proteins	  and	  the	  hnRNPs	  inhibit	  splicing.	  These	  proteins	  will	  be	  discussed	  in	  more	  detail	  in	  later	  sections.	  The	  proteins	  SF1	  and	  U2	  auxiliary	  factor	  (U2AF)	  are	  also	  necessary	  for	  proper	  spliceosome	  assembly.	  SF1	  and	  U2AF	  are	  involved	  in	  the	  initial	  recognition	  of	  specific	  sequences	  within	  introns	  early	  in	  spliceosomal	  assemble.	  The	  sequences	  that	  SF1	  and	  U2AF	  bind	  to	  will	  be	  discussed	  later.	  Other	  factors,	  like	  helicases	  and	  kinases,	  are	  necessary	  for	  progression	  of	  the	  different	  reactions	  of	  RNA	  splicing	  (23).	  Helicases	  are	  necessary	  for	  unwinding	  the	  RNA	  during	  RNA	  splicing	  and	  promoting	  the	  release	  of	  the	  final	  spliced	  mRNA	  from	  the	  spliceosome.	  The	  main	  helicases	  involved	  are	  Prp16,	  Sub2,	  Prp5,	  Prp28,	  Prp22,	  Brr2,	  Prp2,	  and	  Prp43	  (24).	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Many	  of	  the	  other	  known	  proteins	  thought	  to	  be	  part	  of	  the	  spliceosome	  have	  not	  been	  extensively	  studied	  and	  their	  function	  is	  unknown.	  	  The	  spliceosome	  is	  necessary	  for	  defining	  what	  sequences	  are	  exons	  and	  what	  sequences	  are	  introns.	  Exon	  definition	  is	  the	  process	  by	  which	  exonic	  sequences	  in	  the	  RNA	  are	  differentiated	  from	  the	  introns.	  Several	  sequences	  that	  participate	  in	  exon	  definition	  are	  the	  5’-­‐splice	  site	  GU,	  polypyrimidine	  tract	  (PY),	  branch	  point	  A,	  and	  the	  3’-­‐splice	  site	  AG	  (25,26).	  The	  U1	  snRNP	  binds	  to	  the	  5’splice	  site,	  SF1	  and	  U2	  snRNP	  bind	  to	  the	  branch	  point,	  U2AF	  65kDa	  subunit	  binds	  to	  the	  polypyrimidine	  tract,	  and	  the	  U2AF	  35kDa	  subunit	  binds	  to	  the	  3’	  splice	  site.	  The	  snRNPs	  bind	  to	  the	  intronic	  sequences	  in	  a	  stepwise	  fashion	  though	  the	  assembly	  of	  different	  complexes	  (Fig	  2).	  The	  first	  complexes	  that	  form	  are	  called	  either	  the	  E	  complex	  or	  H	  complex.	  The	  H	  complex	  is	  not	  part	  of	  the	  canonical	  splicing	  pathway.	  The	  H	  complex	  is	  named	  after	  the	  hnRNPs,	  which	  can	  bind	  initially	  to	  the	  pre-­‐mRNA.	  The	  hnRNPs	  can	  bind	  to	  sequences	  in	  the	  pre-­‐mRNA	  and	  prevent	  the	  formation	  of	  E	  complex.	  The	  competition	  between	  these	  complexes	  is	  a	  target	  for	  regulation	  of	  RNA	  splicing	  (23,27).	  For	  splicing	  to	  occur,	  E	  complex	  must	  form	  instead	  of	  H	  complex.	  The	  U1	  snRNP	  binds	  to	  the	  5’	  splice	  site	  and	  initiates	  the	  assembly	  of	  E	  complex.	  Also,	  E	  complex	  formation	  requires	  the	  binding	  of	  the	  65	  kDa	  subunit	  of	  U2AF	  to	  the	  polypyrimidine	  tract	  and	  the	  35	  kDa	  subunit	  of	  U2AF	  to	  the	  3’	  splice	  site.	  SF1	  binding	  to	  the	  branch	  point	  completes	  the	  formation	  of	  the	  E	  complex.	  Next,	  A	  complex	  forms	  when	  U2	  snRNP	  is	  recruited	  to	  the	  branchpoint	  and	  replaces	  the	  SF1	  protein.	  The	  binding	  of	  U2	  snRNP	  is	  facilitated	  by	  the	  65	  kDa	  subunit	  of	  U2AF	  in	  an	  ATP-­‐dependent	  manner.	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The	  B	  complex	  is	  the	  next	  complex	  to	  form	  when	  the	  snRNPs	  U4,	  U5,	  and	  U6	  are	  added	  to	  the	  spliceosome	  complex.	  The	  U4/U5/U6	  snRNPs	  form	  a	  tri-­‐snRNP	  
Figure 2: The assembly of the spliceosomal complexes. 5’ splice site = GU, 3’ splice site = 









particle	  that	  forms	  stabile	  interactions	  with	  the	  rest	  of	  the	  spliceosomal	  components.	  The	  B	  complex	  undergoes	  significant	  rearrangement	  and	  during	  this	  rearrangement	  the	  U1	  snRNP	  and	  the	  U4	  snRNP	  are	  lost	  from	  the	  complex.	  The	  completion	  of	  the	  rearrangement	  of	  the	  B	  complex	  produces	  the	  C	  complex.	  The	  C	  complex	  is	  the	  “catalysis	  complex”	  and	  this	  complex	  facilitates	  the	  transesterification	  reactions	  that	  ultimately	  remove	  the	  intron	  and	  join	  the	  exons	  together	  (26,28).	  The	  first	  transesterification	  reaction	  produces	  a	  free	  5’	  exon	  and	  an	  intron	  lariat	  still	  connected	  to	  the	  3’	  exon.	  Further	  rearrangement	  occurs	  and	  the	  second	  transesterification	  reaction	  joins	  the	  2	  exons	  together	  and	  removes	  the	  intron	  lariat.	  With	  the	  removal	  of	  the	  intron	  lariat,	  the	  spliceosome	  has	  completed	  the	  splicing	  of	  the	  2	  exons	  and	  the	  final	  mRNA	  has	  been	  produced.	  	  
C.	  Cis-­‐acting	  Elements	  Involved	  in	  RNA	  Splicing	  
	   In	  addition	  to	  the	  sequences	  within	  the	  intron	  that	  are	  recognized	  by	  the	  components	  of	  the	  spliceosome,	  there	  are	  also	  sequences	  within	  exons	  that	  enhance	  or	  inhibit	  exon	  definition.	  The	  sequences	  are	  termed	  exonic	  splicing	  enhancers	  (ESE)	  or	  exonic	  splicing	  silencers	  (ESS).	  ESEs	  are	  sequences	  within	  exons	  that	  enhance	  splicing	  of	  that	  exon	  by	  recruiting	  SR	  proteins	  that	  are	  a	  family	  of	  proteins	  known	  to	  enhance	  splicing.	  Together,	  the	  ESE	  and	  SR	  proteins	  promote	  exon	  definition	  by	  aiding	  in	  the	  recruitment	  of	  spliceosomal	  components	  like	  U1	  snRNP	  and	  both	  subunits	  of	  U2AF.	  The	  family	  of	  SR	  proteins	  includes	  SRSF	  1-­‐12	  (29,30).	  SR	  protein	  are	  able	  to	  recognize	  the	  ESE	  sequences	  due	  to	  their	  RNA	  recognition	  motif	  (RRM)	  domain.	  In	  many	  cases	  the	  ESE	  sequences	  are	  highly	  degenerative,	  but	  the	  SR	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proteins	  are	  able	  to	  recognize	  and	  bind	  to	  the	  sequences	  that	  are	  specific	  for	  a	  particular	  SR	  protein	  (31).	  	  
	   Exonic	  splicing	  silencers	  are	  also	  important	  for	  the	  proper	  regulation	  of	  RNA	  splicing.	  Like	  the	  ESEs,	  the	  ESSs	  are	  also	  highly	  degenerative	  sequences	  found	  within	  the	  exons	  of	  mRNA.	  The	  ESS	  is	  the	  cis-­‐acting	  element	  found	  within	  the	  RNA	  and	  one	  of	  the	  main	  trans-­‐acting	  factors	  that	  binds	  to	  the	  ESS	  sequence	  are	  the	  hnRNPs.	  By	  binding	  to	  the	  ESSs	  within	  the	  exons,	  hnRNPs	  will	  lead	  to	  skipping	  of	  that	  exon	  (32).	  The	  combination	  of	  the	  ESS	  and	  hnRNPs	  prevent	  exon	  definition	  	  
	   Interestingly,	  some	  exons	  can	  contain	  both	  an	  ESE	  and	  an	  ESS.	  One	  example	  of	  a	  juxtaposed	  ESS/ESE	  occurs	  in	  the	  bovine	  papillomavirus	  type	  1	  (BVP-­‐1)	  transcript.	  Exon	  2	  of	  the	  BVP-­‐1	  transcript	  contains	  both	  an	  ESE	  and	  an	  ESS.	  The	  ESE	  is	  required	  for	  the	  splicing	  of	  exon	  2	  and	  the	  ESS	  that	  is	  immediately	  downstream	  of	  the	  ESS	  will	  repress	  the	  splicing	  of	  exon	  2	  (33).	  The	  exact	  trans-­‐acting	  factors	  that	  are	  involved	  in	  the	  function	  of	  the	  ESS	  and	  ESE	  of	  BVP-­‐1	  are	  not	  known.	  Other	  examples	  of	  juxtaposed	  ESE	  and	  ESS	  will	  be	  discussed	  in	  later	  sections.	  	  
	   In	  addition	  to	  ESSs	  and	  ESEs,	  there	  are	  sequences	  in	  introns	  that	  enhance	  or	  inhibit	  splicing.	  These	  sequences	  are	  intronic	  splicing	  enhancers	  (ISE)	  and	  intronic	  splicing	  silencers	  (ISS).	  Like	  the	  ESE	  and	  ESS	  sequences,	  the	  ISEs	  and	  ISSs	  are	  bound	  by	  trans-­‐acting	  factors.	  The	  factors	  that	  bind	  to	  ISEs	  enhance	  the	  inclusion	  of	  exons	  in	  the	  final	  transcript.	  For	  example,	  the	  ISE	  defined	  by	  the	  sequence	  UGCAUG	  is	  found	  within	  some	  transcripts	  in	  neural	  tissue.	  FOX-­‐1	  and	  FOX-­‐2	  bind	  the	  ISE	  in	  neural	  tissue	  and	  in	  the	  case	  of	  the	  N30	  exon	  in	  myosin	  heavy	  chain	  B,	  binding	  of	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these	  proteins	  to	  the	  ISE	  is	  necessary	  for	  exon	  inclusion,	  while	  in	  non-­‐neural	  tissues	  in	  the	  absence	  of	  these	  proteins	  the	  N30	  exon	  is	  skipped	  (34,35).	  ISS	  sequences	  are	  bound	  by	  trans-­‐acting	  factors	  that	  inhibit	  the	  splicing	  of	  exons.	  One	  such	  factor	  is	  polypyrimidine	  tract-­‐binding	  protein	  (PTB),	  which	  binds	  to	  the	  ISS	  found	  within	  the	  c-­‐src	  mRNA.	  PTB	  prevents	  the	  binding	  of	  the	  65kDa	  subunit	  of	  U2AF	  to	  the	  polypyrimidine	  tract	  and	  thereby	  recruitment	  of	  U2	  snRNP.	  As	  a	  result,	  the	  downstream	  N1	  exon	  is	  excluded	  from	  the	  mature	  mRNA	  (36,37).	  The	  ISE	  and	  ISS	  provide	  another	  layer	  of	  regulation	  to	  the	  complicated	  process	  of	  RNA	  splicing.	  	   
 D.	  SR	  Proteins 
	   The	  SR	  proteins	  are	  a	  family	  of	  RNA	  binding	  proteins	  that	  primarily	  enhance	  splicing.	  The	  name	  is	  derived	  from	  a	  domain	  in	  the	  C-­‐terminus	  that	  is	  rich	  in	  serines	  and	  arginines	  (RS	  domain).	  In	  addition	  to	  the	  RS	  domain,	  SR	  proteins	  contain	  one	  or	  two	  RNA	  recognition	  motifs	  (RRM).	  In	  regard	  to	  function,	  the	  RRM	  is	  used	  for	  binding	  to	  sequences	  within	  RNA,	  while	  the	  RS	  domain	  can	  promote	  RNA	  splicing	  and	  spliceosome	  assembly	  by	  interacting	  via	  protein-­‐protein	  interactions	  between	  SR	  proteins	  and	  spliceosomal	  components	  (38,39).	  The	  SR	  proteins	  are	  typically	  described	  as	  proteins	  that	  bind	  to	  an	  ESE	  and	  promote	  splicing.	  This	  may	  involve	  the	  recruitment	  of	  spliceosomal	  machinery	  and/or	  may	  also	  prevent	  the	  binding	  of	  inhibitory	  proteins	  to	  a	  nearby	  or	  overlapping	  ESS	  (21,40,41).	  A	  juxtaposed	  ESS	  and	  ESE	  regulate	  the	  splicing	  of	  HIV-­‐1	  tat	  gene.	  The	  SR	  protein	  SRSF2	  binds	  to	  an	  ESE	  that	  overlaps	  with	  the	  ESS	  that	  is	  a	  binding	  site	  for	  the	  splicing	  inhibitor,	  hnRNP	  A1	  (42).	  Similarly,	  juxtaposed	  regulatory	  elements	  occur	  with	  the	  regulation	  of	  the	  mutually	  exclusive	  exons,	  exon	  2	  and	  exon	  3,	  of	  the	  α-­‐tropomyosin	  pre-­‐mRNA.	  Exon	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2	  is	  included	  in	  smooth	  muscle	  cells	  and	  exon	  3	  is	  included	  in	  most	  other	  cell	  types.	  The	  inclusion	  of	  exon	  2	  requires	  the	  activity	  of	  the	  SR	  protein,	  SRSF7.	  SRSF7	  binds	  to	  an	  ESE	  in	  exon	  2	  and	  prevents	  the	  binding	  of	  the	  splicing	  of	  inhibitors	  hnRNP	  H	  and	  hnRNP	  F	  to	  a	  juxtaposed	  ESS	  (43).	  Competition	  between	  these	  splicing	  enhancers	  and	  silencers	  plays	  an	  essential	  role	  in	  the	  proper	  regulation	  of	  RNA	  splicing.	  	  
E.	  The	  Regulation	  of	  SR	  Proteins	  
	   Phosphorylation	  of	  SR	  proteins	  is	  the	  major	  posttranslational	  modification	  that	  enhances	  their	  function.	  When	  SR	  proteins	  are	  inactive	  and	  not	  participating	  in	  splicing,	  they	  are	  localized	  to	  nuclear	  speckles.	  Nuclear	  speckles	  are	  located	  in	  interchromatin	  regions	  and	  are	  regions	  within	  the	  nucleus	  containing	  high	  concentrations	  of	  splicing	  factors	  (44-­‐46).	  Increased	  phosphoylation	  can	  cause	  the	  SR	  proteins	  to	  leave	  the	  speckle	  and	  move	  to	  sites	  of	  transcription,	  where	  they	  can	  bind	  to	  pre-­‐mRNA	  and	  cause	  changes	  in	  RNA	  splicing	  (44).	  Phosphorylation	  status	  of	  the	  SR	  proteins	  also	  enhances	  the	  movement	  of	  SR	  proteins	  from	  the	  nucleus	  to	  the	  cytoplasm.	  When	  the	  SR	  proteins	  are	  partially	  dephosphorylated,	  it	  promotes	  their	  exit	  from	  the	  nucleus	  bound	  to	  the	  spliced	  mRNA	  through	  interaction	  between	  the	  SR	  protein	  and	  TAP	  export	  protein	  (47-­‐49).	  To	  re-­‐enter	  the	  nucleus,	  the	  SR	  protein	  must	  be	  re-­‐phosphorylated.	  The	  specific	  residues	  on	  SR	  proteins	  that	  are	  phosphorylated	  and	  activate	  shuttling	  remain	  to	  be	  identified.	  	  
Phosphorylation	  of	  SR	  proteins	  involves	  specific	  kinases.	  The	  SR	  protein	  kinases	  (SRPK)	  are	  made	  up	  of	  SRPK1	  and	  SRPK2.	  SRPK1	  is	  required	  for	  SR	  protein	  re-­‐entry	  into	  the	  nucleus	  (50).	  SRPK2	  has	  similar	  enzymatic	  activity	  when	  compared	  
 13 
to	  SRPK1	  but	  little	  is	  known	  about	  SRPK2	  (51).	  Cdc2-­‐like	  kinase/serine/threonine/tyrosine	  kinase	  (Clk/Sty)	  is	  another	  kinase	  that	  can	  phosphorylate	  SR	  proteins.	  Clk/Sty	  has	  an	  RS	  domain	  like	  the	  SR	  proteins	  and	  it	  is	  found	  within	  nuclear	  speckles,	  where	  the	  phosphorylation	  of	  SR	  protein	  by	  Clk/Sty	  regulates	  SR	  protein	  movement	  within	  the	  nucleus	  (52,53).	  In	  this	  regard,	  increasing	  the	  activity	  of	  Clk/Sty	  by	  overexpression	  increased	  phosphorylation	  of	  SRSF1	  and	  causes	  SRSF1	  to	  leave	  the	  nuclear	  speckle	  and	  move	  to	  transcription	  site	  (53).	  Clk/Sty	  can	  also	  phosphorylate	  and	  activate	  most	  other	  SR	  proteins	  in	  addition	  to	  SRSF1	  (53,54).	  In	  addition	  to	  SRPK	  and	  Clk/Sty,	  Akt2	  is	  another	  kinase	  that	  can	  phosphorylate	  SR	  proteins.	  Akt2	  is	  activated	  by	  insulin	  signaling	  and	  phosphorylates	  SRp40.	  The	  phosphorylation	  of	  SRp40	  promotes	  the	  binding	  of	  SRp40	  and	  subsequent	  splicing	  of	  PKC	  mRNA,	  which	  produces	  the	  PKCβII	  protein.	  The	  production	  of	  PKCβII	  is	  important	  for	  insulin’s	  action	  toward	  increasing	  glucose	  uptake	  (55,56).	  Furthermore,	  Akt	  2	  can	  phosphorylate	  Clk/Sty	  increasing	  its	  activity	  (57).	  Thus,	  Akt	  2	  has	  both	  cytoplasmic	  and	  nuclear	  activity.	  	  
F.	  The	  hnRNPs	  
	   The	  hnRNPs	  were	  originally	  described	  as	  proteins	  that	  associated	  with	  pre-­‐mRNA.	  They	  were	  discovered	  in	  rapidly	  dividing	  cells,	  where	  they	  are	  almost	  as	  highly	  expressed	  as	  histones	  (32).	  The	  hnRNPs	  can	  function	  in	  many	  areas	  of	  gene	  expression,	  like	  transcription,	  RNA	  splicing,	  translation,	  RNA	  export	  from	  the	  nucleus,	  mRNA	  stability,	  and	  chromatin	  remodeling	  (32,58).	  Interestingly,	  overlapping	  functions	  of	  the	  hnRNPs	  in	  the	  different	  areas	  of	  gene	  expression	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demonstrates	  that	  they	  play	  a	  major	  role	  in	  proper	  gene	  expression	  and	  cell	  function.	  	  




















hnRNP R1 82kDa RRM# RRM#RRM# RGG#
R2 (minus 38 aa) 
65kDa hnRNP K KH# KH# KH#RGG# KI KNS#
43kDa RRM# SRGY# RGG#hnRNP G 
Figure 3: Structures of some of the hnRNP proteins. The molecular 
weights of the proteins are listed on the right. The RRM represents the 
RNA recognition motifs. The KH represents the K-homology domain. The 
RGG indicates the arginine-glycine-glycine rich domain. The M9 domain is 
a nucleo-cytoplasmic export signal. The KNS is the hnRNP K nuclear 
shuttling domain and the KI is the K interactive domain. The serine, 
arginine, glycine, and tyrosine domain (SRGY) domain found is some 
hnRNPs. The function of some of these domains is unknown.  Adapted 
from Martinez-Contreras et al. 2007 and Hung et al. 2008. 
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III.	  HnRNP	  K	  
A.	  Introduction	  and	  Protein	  Structure	   
HnRNP	  K	  is	  one	  of	  the	  more	  widely	  studied	  hnRNPs.	  HnRNP	  K	  regulates	  many	  areas	  of	  gene	  expression	  from	  transcription	  to	  translation.	  HnRNP	  K	  is	  a	  65	  kDa	  protein	  and	  has	  three	  K	  homology	  domains	  (KH)	  that	  are	  required	  for	  binding	  to	  cytidine-­‐rich	  sequences	  found	  within	  both	  DNA	  and	  RNA.	  HnRNP	  K	  is	  most	  similar	  to	  hnRNP	  E1	  and	  hnRNP	  E2,	  which	  both	  have	  KH	  domains	  and	  bind	  to	  cytidine-­‐rich	  sequences	  (64-­‐66).	  The	  structure	  of	  hnRNP	  K	  can	  vary	  as	  four	  hnRNP	  K	  transcripts	  can	  be	  produced	  by	  alternative	  splicing,	  but	  the	  function	  of	  these	  different	  spliced	  transcripts	  remains	  to	  be	  determined	  (67,68).	  The	  KH	  domains	  in	  hnRNP	  K	  bind	  to	  cytidine-­‐rich	  sequences	  and	  these	  sequences	  can	  be	  a	  single	  stretch	  of	  cytidines	  to	  as	  many	  as	  a	  group	  of	  three	  cytidine-­‐rich	  elements	  within	  the	  nucleotide	  sequences	  (65,69).	  The	  three	  KH	  domains	  are	  required	  for	  optimal	  binding	  as	  one	  KH	  domain	  alone	  weakly	  binds	  cytidine-­‐rich	  nucleotides	  (70).	  HnRNP	  K	  not	  only	  recognizes	  these	  sequences	  in	  RNA	  but	  also	  recognizes	  them	  within	  DNA	  (71,72).	  The	  ability	  of	  hnRNP	  K	  to	  bind	  to	  both	  DNA	  and	  RNA	  contributes	  to	  the	  ability	  of	  hnRNP	  K	  to	  regulate	  multiple	  levels	  of	  gene	  expression.	  	  
	   HnRNP	  K	  also	  contains	  other	  important	  domains	  that	  contribute	  to	  its	  function	  and	  interactions	  with	  other	  proteins/pathways.	  These	  are	  involved	  in	  protein/protein	  interactions	  and	  affect	  the	  cellular	  localization	  of	  hnRNP	  K.	  The	  K-­‐protein	  interactive	  (KI)	  domain	  is	  responsible	  for	  some	  of	  the	  known	  protein-­‐protein	  interactions	  and	  is	  not	  present	  in	  the	  other	  hnRNPs	  that	  bind	  to	  cytidine-­‐
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rich	  sequences,	  like	  hnRNPs	  E1	  and	  E2	  (73).	  The	  KI	  domain	  is	  known	  to	  promote	  interaction	  with	  SH3	  domains	  in	  other	  proteins.	  One	  known	  group	  of	  proteins	  containing	  SH3	  domains	  that	  interact	  with	  hnRNP	  K	  is	  the	  Src	  kinase	  family	  (74).	  It	  is	  not	  clear	  whether	  the	  KI	  domain	  is	  responsible	  for	  all	  the	  protein-­‐protein	  interactions	  between	  hnRNP	  K	  and	  its	  partners.	  HnRNP	  K	  does	  interact	  with	  an	  extensive	  array	  of	  different	  proteins	  that	  are	  involved	  in	  signal	  transduction,	  chromatin	  remodeling,	  transcription,	  translation,	  and	  RNA	  splicing	  (73).	  HnRNP	  K	  also	  contains	  a	  nuclear	  localization	  signal	  (NLS)	  and	  nuclear	  shuttling	  domain	  (KNS)	  that	  presumably	  affect	  the	  localization	  of	  hnRNP	  K;	  however,	  the	  exact	  function	  of	  the	  KNS	  and	  NLS	  within	  hnRNP	  K	  has	  not	  been	  determined	  (73,75).	  Phosphorylation	  of	  hnRNP	  K	  does	  regulate	  its	  intracellular	  location	  and	  causes	  the	  cytoplasmic	  accumulation	  of	  hnRNP	  K	  (76).	  Lastly,	  hnRNP	  K	  contains	  a	  RGG	  domain,	  which	  can	  be	  methylated	  and	  the	  mutation	  of	  this	  domain	  decreases	  the	  nuclear	  localization	  of	  hnRNP	  K	  (73,77).	  	  
	   HnRNP	  K	  can	  be	  extensively	  post-­‐translationally	  modified	  by	  phosphorylation,	  methylation,	  sumoylation,	  and	  ubiqitination	  (73,78).	  HnRNP	  K	  is	  phosphorylated	  by	  JNK,	  ERK,	  Protein	  kinase	  C	  (PKC),	  and	  the	  Src-­‐family	  of	  kinases	  (76,79-­‐81).	  Additionally,	  the	  RGG	  domain	  within	  hnRNP	  K	  is	  methylated	  at	  seven	  sites;	  Arg256,	  Arg258,	  Arg268,	  Arg287,	  Arg296,	  Arg299,	  and	  Arg303	  (82-­‐84).	  Protein	  arginine	  methyltransferase	  1	  (PRMT1)	  has	  so	  far	  been	  the	  only	  arginine	  methyltransferase	  identified	  to	  methylate	  hnRNP	  K	  at	  these	  sites	  (82).	  Whether	  or	  not	  other	  methyltransferases	  can	  methylate	  hnRNP	  K	  has	  yet	  to	  be	  determined.	  Lastly,	  hnRNP	  K	  is	  sumoylated	  by	  the	  E3	  ligase,	  Pc2,	  at	  lysine	  422	  (85)	  and	  can	  also	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be	  ubiquinated	  (86).	  The	  sumolyation	  of	  hnRNP	  K	  enhances	  its	  transcriptional	  activity	  (85).	  The	  ubiquitination	  of	  hnRNP	  K	  is	  required	  for	  proteasomal	  degradation	  of	  the	  protein	  (85,86).	  The	  roles	  of	  the	  many	  of	  these	  post-­‐translational	  modifications	  of	  hnRNP	  K	  will	  be	  discussed	  in	  the	  next	  few	  sections.	  The	  post-­‐translational	  modifications	  of	  hnRNP	  K	  have	  major	  implications	  in	  regulating	  the	  function	  of	  hnRNP	  K	  and	  these	  modifications	  link	  hnRNP	  K	  with	  many	  signaling	  pathways	  and	  a	  wide	  array	  of	  gene	  expression	  processes.	  
B.	  Transcriptional	  Regulation	  by	  HnRNP	  K	  
	   The	  transcriptional	  activity	  of	  hnRNP	  K	  has	  been	  extensively	  studied	  with	  respect	  to	  p53.	  The	  protein	  p53	  is	  a	  tumor	  suppressor	  that	  is	  responsible	  for	  promoting	  and	  maintaining	  genomic	  stability	  following	  DNA	  damage.	  DNA	  damage	  increases	  p53	  transcriptional	  activity	  that	  leads	  to	  cell	  cycle	  arrest	  or	  apoptosis	  (87,88).	  HnRNP	  K	  is	  a	  transcriptional	  cofactor	  for	  p53	  and	  promotes	  the	  transcription	  of	  p53	  target	  genes	  by	  interacting	  with	  p53	  on	  the	  promoters	  of	  genes.	  With	  a	  depletion	  of	  hnRNP	  K,	  p53	  was	  unable	  to	  bind	  as	  effectively	  to	  the	  promoters	  of	  gene	  for	  which	  it	  activates	  (86).	  More	  recent	  evidence	  has	  established	  a	  role	  for	  the	  posttranslational	  modifications	  of	  hnRNP	  K,	  such	  as	  methylation	  and	  sumoylation,	  as	  they	  relate	  to	  the	  transcriptional	  activity	  of	  p53.	  Arginine	  methylation	  of	  hnRNP	  K	  is	  induced	  due	  to	  UV	  damage	  and	  is	  required	  for	  p53	  transcriptional	  activity.	  Inhibition	  of	  the	  methylation	  caused	  a	  decrease	  in	  the	  binding	  of	  p53	  to	  the	  promoter	  of	  its	  target	  genes	  and	  decreased	  transcription	  of	  those	  targets	  (89).	  Additionally,	  research	  has	  identified	  that	  DNA	  damage	  induced	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stabilization	  of	  hnRNP	  K.	  The	  stabilization	  of	  hnRNP	  K	  is	  caused	  by	  a	  decrease	  in	  the	  human	  double	  minute	  2	  (HDM2)-­‐mediated	  ubiquitin-­‐dependent	  degradation	  of	  hnRNP	  K	  (86).	  The	  decease	  in	  ubiquitination	  was	  due	  to	  the	  increase	  in	  sumoylation	  of	  hnRNP	  K.	  Small	  ubiquitin-­‐related	  modifier	  (SUMO)	  is	  covalently	  attached	  at	  lysine	  422	  of	  hnRNP	  K.	  DNA	  damage	  caused	  by	  UV	  radiation	  increased	  the	  sumoylation	  of	  hnRNP	  K	  either	  by	  Pc2	  (85)	  or	  PIAS3	  (90),	  which	  are	  both	  E3	  SUMO-­‐protein	  ligases.	  In	  addition	  to	  the	  stabilization,	  sumoylation	  of	  hnRNP	  K	  is	  required	  for	  hnRNP	  K	  to	  co-­‐activate	  p53	  transcription	  when	  DNA	  is	  damaged	  (85,90).	  The	  data	  suggests	  that	  the	  sumoylation	  of	  hnRNP	  not	  only	  protects	  against	  its	  degradation,	  but	  also	  is	  necessary	  for	  the	  interaction	  between	  p53	  and	  hnRNP	  K	  that	  is	  necessary	  for	  the	  transcriptional	  activity	  of	  p53.	  	  
	   HnRNP	  K	  has	  also	  been	  identified	  as	  a	  transcriptional	  regulator	  of	  genes	  other	  than	  p53.	  One	  such	  gene	  is	  c-­‐myc,	  which	  is	  an	  oncogenic	  transcription	  factor	  (91).	  HnRNP	  K	  binds	  to	  the	  promoter	  of	  c-­‐myc	  at	  a	  cytidine/thymidine-­‐rich	  (CT)	  element	  (92).	  By	  overexpressing	  hnRNP	  K	  protein	  in	  cells,	  c-­‐myc	  promoter	  activity	  increases,	  as	  long	  as	  TFIID	  TATA	  box-­‐binding	  protein	  is	  co-­‐expressed	  (71).	  Also,	  hnRNP	  K	  enhances	  transcription	  of	  the	  low-­‐density	  lipoprotein	  receptor	  (LDLR).	  HnRNP	  K	  binds	  to	  a	  CT-­‐rich	  element	  in	  the	  promoter	  of	  LDLR	  and	  causes	  an	  increase	  in	  the	  expression	  of	  LDLR	  (93).	  In	  contrast	  to	  c-­‐myc	  and	  LDLR,	  hnRNP	  K	  binds	  to	  another	  CT-­‐rich	  element	  in	  the	  promoter	  of	  the	  thymidine	  kinase	  gene	  and	  causes	  a	  repression	  of	  transcription	  (94).	  Lastly,	  hnRNP	  K	  inhibits	  the	  transcription	  of	  the	  angiotensinogen	  gene	  in	  the	  kidney.	  HnRNP	  K	  binds	  to	  the	  promoter	  of	  angiotensinogen	  and	  along	  with	  hnRNP	  F,	  hnRNP	  K	  inhibits	  its	  transcription	  in	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kidney	  cells	  (95).	  This	  suggests	  that	  activation	  versus	  inhibition	  of	  transcription	  involves	  differing	  sets	  of	  binding	  partners.	  	  
	  C.	  Translational	  Regulation	  by	  HnRNP	  K	  	  
	   The	  idea	  that	  hnRNP	  K	  could	  potentially	  be	  involved	  in	  regulating	  translation	  came	  from	  the	  observation	  that	  hnRNP	  K	  can	  bind	  to	  the	  translation	  elongation	  factor,	  EF-­‐1α	  (75).	  EF-­‐1α	  is	  responsible	  for	  regulating	  the	  rate	  of	  translation	  by	  transferring	  aminoacyl-­‐transfer	  RNAs	  to	  the	  ribosome	  (96).	  However,	  whether	  or	  not	  this	  interaction	  has	  any	  role	  in	  regulating	  translation	  is	  unknown.	  HnRNP	  K	  can	  indirectly	  regulate	  translation	  through	  increasing	  the	  cellular	  content	  of	  the	  eukaryotic	  translation	  initiation	  factor	  4E	  (eIF4E).	  EIF4E	  is	  a	  translation	  initiation	  factor	  that	  aids	  the	  interaction	  of	  the	  ribosome	  with	  the	  cap	  of	  mRNAs.	  This	  interaction	  is	  the	  rate-­‐limiting	  step	  of	  protein	  synthesis	  (97).	  HnRNP	  K	  binds	  to	  a	  cytidine-­‐rich	  element	  in	  the	  eIF4E	  promoter	  and	  increases	  the	  expression	  eIF4E	  (98).	  The	  increase	  in	  eIF4E	  expression	  by	  the	  over-­‐expression	  of	  hnRNP	  K	  causes	  an	  overall	  increase	  in	  the	  rate	  of	  translation	  in	  cells	  and	  this	  increase	  in	  global	  translation	  caused	  by	  the	  increase	  in	  eIF4E	  can	  trigger	  an	  increase	  in	  cell	  transformation	  (98).	  	  HnRNP	  K	  can	  also	  inhibit	  translation	  by	  binding	  to	  an	  element	  found	  in	  the	  3’	  UTR	  of	  some	  RNAs.	  HnRNP	  K	  binds	  to	  a	  CU-­‐rich	  element	  called	  the	  differentiation	  control	  element	  (DICE)	  that	  is	  found	  in	  the	  3’	  UTR	  of	  the	  15-­‐lipoxygenase	  gene	  (LOX)	  (99).	  The	  binding	  of	  hnRNP	  K	  and	  also	  hnRNP	  E1/E2	  to	  this	  element	  inhibits	  translation	  by	  preventing	  the	  recruitment	  and	  assembly	  of	  the	  ribosome	  (100).	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Some	  reports	  have	  indicated	  that	  phosphorylation	  has	  a	  role	  in	  regulating	  the	  translational	  activity	  of	  hnRNP	  K.	  HnRNP	  K	  will	  bind	  to	  c-­‐Src,	  which	  causes	  c-­‐Src	  to	  phosphorylate	  hnRNP	  K	  at	  tyrosine	  residues	  Y72,	  Y225,	  Y230,	  Y234,	  Y236,	  and	  Y380.	  The	  phosphorylation	  of	  hnRNP	  K	  by	  c-­‐Src	  inhibits	  hnRNP	  K	  binding	  to	  DICE	  within	  the	  LOX	  mRNA.	  The	  ability	  of	  c-­‐Src	  to	  phosphorylate	  hnRNP	  K	  prevents	  the	  translational	  silencing	  of	  LOX	  mRNA	  in	  cells	  by	  hnRNP	  K	  (79).	  Phosphorylation	  of	  hnRNP	  K	  by	  ERK	  also	  causes	  an	  increase	  in	  the	  translational	  repression	  by	  hnRNP	  K.	  When	  ERK	  is	  activated,	  it	  phosphorylates	  hnRNP	  K	  at	  the	  serine	  resides,	  S284,	  and	  S353.	  The	  phosphorylation	  at	  these	  serine	  residues	  is	  required	  for	  the	  translational	  inhibition	  by	  hnRNP	  K	  on	  RNAs	  that	  contain	  a	  3’	  UTR	  DICE	  element	  in	  cells.	  However,	  the	  ability	  of	  hnRNP	  K	  to	  bind	  to	  RNA	  that	  contains	  a	  DICE	  in	  vitro	  was	  not	  dependent	  on	  phosphorylation	  by	  ERK.	  The	  phosphorylation	  of	  hnRNP	  K	  by	  ERK	  causes	  it	  to	  translocate	  from	  the	  nucleus	  to	  the	  cytoplasm.	  The	  accumulation	  of	  hnRNP	  K	  in	  the	  cytoplasm	  coincides	  with	  the	  increase	  in	  translational	  repression	  (76).	  Whether	  hnRNP	  K	  can	  inhibit	  the	  translation	  of	  other	  RNAs	  besides	  the	  LOX	  gene	  and	  if	  this	  repression	  requires	  a	  DICE	  remains	  to	  be	  determined.	  	  
D.	  RNA	  Splicing	  and	  HnRNP	  K	  
	   The	  involvement	  of	  hnRNP	  K	  in	  RNA	  splicing	  has	  not	  been	  studied	  as	  extensively	  as	  the	  other	  areas	  of	  gene	  expression	  regulated	  by	  hnRNP	  K.	  One	  of	  the	  first	  clues	  that	  hnRNP	  K	  could	  be	  involved	  in	  splicing	  is	  that	  hnRNP	  K	  can	  interact	  with	  a	  number	  of	  known	  splicing	  factors.	  HnRNP	  K	  can	  interact	  with	  splicing	  factors	  like	  hnRNP	  L,	  hnRNP	  A1,	  SFRS7,	  and	  SFRS3	  (101,102).	  The	  first	  evidence	  that	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hnRNP	  K	  is	  involved	  in	  directly	  regulating	  RNA	  splicing	  was	  discovered	  for	  the	  chicken	  β-­‐tropomyosin	  gene.	  HnRNP	  K	  binds	  to	  an	  intronic	  enhancer	  element	  downstream	  of	  exon	  6A	  and	  promotes	  the	  inclusion	  of	  the	  alternative	  exon	  6A	  in	  the	  final	  transcript	  (103).	  More	  recently	  hnRNP	  K	  was	  discovered	  as	  a	  splicing	  regulator	  of	  the	  Bcl-­‐x	  pre-­‐mRNA	  (104).	  Bcl-­‐x	  is	  a	  regulator	  of	  apoptosis	  and	  its	  pre-­‐mRNA	  can	  produce	  two	  isoforms	  of	  opposing	  function.	  The	  isoforms	  of	  Bcl-­‐x	  are	  Bcl-­‐xL,	  which	  is	  anti-­‐apoptotic,	  and	  Bcl-­‐xS,	  which	  is	  a	  smaller	  protein	  and	  is	  pro-­‐apoptotic	  (105).	  HnRNP	  K	  binds	  to	  a	  silencer	  element	  in	  the	  Bcl-­‐x	  pre-­‐mRNA	  and	  represses	  the	  production	  of	  the	  Bcl-­‐xs	  isoform	  (104).	  The	  involvement	  of	  hnRNP	  K	  in	  the	  regulation	  of	  RNA	  splicing	  also	  includes	  the	  regulation	  of	  the	  splicing	  of	  the	  synaptosomal-­‐associated	  protein	  25	  (Snap25)	  mRNA	  during	  neuronal	  differentiation.	  Exon	  5b	  is	  included	  in	  the	  mRNA	  during	  differentiation	  and	  development,	  but	  in	  adult	  animals	  and	  developed	  tissues,	  the	  mutually	  exclusive	  exon	  5a	  is	  included	  in	  the	  final	  transcript	  (106,107).	  HnRNP	  K	  promotes	  the	  inclusion	  of	  exon	  5b	  and	  the	  exclusion	  of	  exon	  5a	  by	  binding	  to	  a	  protein	  kinase	  A	  (PKA)-­‐responsive	  RNA	  element	  (KARRE)	  that	  is	  within	  the	  intron	  upstream	  of	  exon	  5a.	  When	  hnRNP	  K	  binds	  to	  the	  KARRE,	  it	  prevents	  the	  binding	  of	  U2AF65	  and	  spliceosomal	  assembly.	  This	  causes	  exon	  5a	  of	  Snap25	  to	  be	  skipped	  (108).	  While	  the	  known	  regulation	  of	  RNA	  splicing	  by	  hnRNP	  K	  is	  limited,	  future	  research	  will	  likely	  define	  other	  RNA	  splicing	  events	  that	  are	  regulated	  by	  hnRNP	  K.	  Additionally,	  the	  interaction	  between	  hnRNP	  K	  and	  other	  splicing	  factors	  likely	  plays	  an	  important	  role	  in	  the	  function	  of	  hnRNP	  K	  as	  a	  splicing	  regulator.	  Further	  research	  is	  required	  to	  understand	  the	  importance	  of	  these	  interactions.	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IV.	  HnRNP	  L	  	  
A.	  Introduction	  and	  Protein	  Structure	  	  
	  	   The	  areas	  of	  gene	  expression	  that	  are	  regulated	  by	  hnRNP	  L	  are	  RNA	  splicing	  and	  translation.	  HnRNP	  L	  is	  a	  65	  kDa	  protein	  that	  has	  4	  RNA	  recognition	  motifs	  (RRM)	  (32).	  The	  RRM	  domains	  of	  hnRNP	  L	  recognize	  a	  cytidine-­‐adenosine	  rich	  element	  within	  RNA	  (109).	  Unlike	  hnRNP	  K,	  hnRNP	  L	  binds	  to	  RNA,	  not	  DNA.	  The	  only	  known	  posttranslational	  modification	  of	  hnRNP	  L	  is	  phosphorylation	  (110-­‐112).	  	  	  
B.	  Translation	  and	  HnRNP	  	  L	  




C.	  RNA	  Splicing	  and	  HnRNP	  L	  	   The	  regulation	  of	  RNA	  splicing	  has	  been	  the	  main	  focus	  of	  the	  research	  surrounding	  hnRNP	  L	  and	  its	  effects	  on	  gene	  expression.	  The	  regulation	  of	  RNA	  splicing	  by	  hnRNP	  L	  was	  first	  identified	  for	  the	  endothelial	  nitric	  oxide	  synthase	  (eNOS)	  mRNA.	  HnRNP	  L	  binds	  to	  a	  set	  of	  CA-­‐repeats	  in	  the	  (eNOS)	  RNA	  sequence	  within	  intron	  13	  and	  activates	  the	  upstream	  5’	  splice	  site	  (109).	  	  Since	  the	  discovery	  that	  hnRNP	  L	  can	  regulate	  splicing,	  a	  number	  of	  studies	  have	  been	  conducted	  that	  provide	  more	  evidence	  for	  the	  role	  of	  hnRNP	  L	  in	  RNA	  splicing.	  	  The	  splicing	  of	  CD45	  mRNA	  has	  been	  extensively	  studied.	  CD45	  is	  a	  transmembrane	  protein	  tyrosine	  phosphatase	  that	  has	  several	  isoforms.	  Within	  the	  CD45	  mRNA	  there	  are	  3	  alternatively	  spliced	  exons,	  exons	  4,	  5,	  and	  6	  that	  encode	  for	  the	  extracellular	  domain	  of	  the	  protein	  (116,117).	  The	  RNA	  splicing	  of	  exon	  4	  of	  the	  CD45	  mRNA	  is	  inhibited	  by	  an	  ESS.	  HnRNP	  L	  is	  the	  trans-­‐acting	  factor	  that	  binds	  to	  the	  ESS	  in	  exon	  4	  and	  causes	  the	  exclusion	  of	  exon	  4	  from	  the	  final	  mature	  mRNA	  (118).	  	  In	  addition	  to	  binding	  to	  the	  ESS,	  hnRNP	  L	  also	  recruits	  another	  hnRNP,	  hnRNP	  A1,	  to	  a	  sequence	  that	  is	  upstream	  of	  the	  5’splice	  site	  of	  exon	  4.	  The	  binding	  of	  both	  hnRNP	  L	  and	  A1	  inhibit	  splicing	  of	  exon	  4	  by	  preventing	  U6	  snRNA	  association,	  thereby	  blocking	  catalysis	  of	  the	  splicing	  reaction	  (119).	  HnRNP	  L	  not	  only	  acts	  to	  inhibit	  splicing	  by	  binding	  directly	  to	  an	  ESS	  element,	  but	  can	  recruit	  proteins	  that	  are	  also	  necessary	  for	  the	  proper	  regulation	  of	  RNA	  splicing.	  	  In	  addition	  to	  regulation	  of	  CD45	  by	  hnRNP	  L,	  a	  protein	  closely	  related	  to	  hnRNP	  L	  known	  as	  hnRNP	  L-­‐Like	  (hnRNP	  LL)	  also	  regulates	  the	  splicing	  of	  CD45	  mRNA.	  These	  two	  proteins	  share	  58%	  amino	  acid	  similarity	  and	  are	  similar	  in	  size.	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HnRNP	  LL	  lacks	  the	  proline-­‐rich	  domain	  that	  is	  found	  in	  hnRNP	  L	  (Fig	  3)	  (120).	  The	  skipping	  of	  all	  the	  exons,	  exons	  4,	  5,	  and	  6	  that	  were	  previously	  discussed	  requires	  not	  only	  hnRNP	  L	  but	  also	  hnRNP	  LL.	  HnRNP	  LL	  binds	  to	  two	  silencer	  elements	  within	  exon	  6.	  The	  binding	  of	  hnRNP	  L	  to	  exon	  4	  and	  the	  binding	  of	  hnRNP	  LL	  and/or	  hnRNP	  L	  to	  exon	  6	  cause	  the	  skipping	  of	  the	  exons	  4,	  5,	  and	  6	  (121).	  This	  suggests	  a	  possible	  compensatory	  mechanism	  between	  hnRNP	  L	  and	  hnRNP	  LL,	  as	  they	  are	  able	  to	  bind	  to	  similar	  silencing	  elements.	  However,	  it	  is	  unknown	  whether	  hnRNP	  LL	  regulates	  the	  splicing	  of	  other	  mRNAs.	  	  HnRNP	  L	  also	  plays	  an	  important	  role	  in	  regulating	  the	  alternative	  splicing	  of	  the	  potassium	  channel	  gene,	  Slo.	  Slo	  contains	  an	  exon	  that	  is	  called	  stress	  axis-­‐regulated	  exon	  (STREX)	  and	  this	  exon	  is	  found	  between	  exon	  18	  and	  exon	  19.	  Within	  the	  STREX	  exon	  there	  are	  CA-­‐repeats	  to	  which	  hnRNP	  L	  binds	  and	  inhibits	  the	  inclusion	  of	  the	  STREX	  exon	  in	  the	  final	  transcript	  of	  Slo.	  Interestingly,	  there	  is	  a	  serine	  residue,	  Ser-­‐513,	  within	  hnRNP	  L	  that	  is	  phosphorylated	  by	  Ca2+/calmodulin-­‐dependent	  protein	  kinase	  IV	  (CaMKIV)	  when	  it	  is	  activated	  by	  membrane	  depolarization.	  The	  phosphorylation	  of	  hnRNP	  L	  enhances	  the	  binding	  of	  hnRNP	  L	  to	  the	  CA-­‐repeats	  within	  STREX	  and	  is	  required	  for	  the	  inhibition	  of	  STREX	  in	  the	  final	  transcript.	  When	  the	  STREX	  exon	  is	  excluded	  from	  the	  final	  transcript	  it	  causes	  the	  production	  of	  potassium	  channels	  with	  slightly	  altered	  properties.	  One	  of	  those	  properties	  includes	  a	  decrease	  in	  the	  Ca2+	  and	  voltage	  sensitivity	  (112,122).	  The	  alteration	  of	  the	  splicing	  of	  Slo	  mRNA	  by	  hnRNP	  L	  is	  necessary	  for	  the	  normal	  function	  of	  the	  potassium	  channel	  after	  membrane	  depolarization.	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A	  final	  example	  that	  has	  been	  well	  studied	  in	  relation	  to	  the	  affect	  of	  hnRNP	  L	  on	  its	  splicing	  is	  caspase-­‐9	  mRNA.	  Caspase-­‐9	  is	  an	  important	  protein	  in	  the	  apoptotic	  pathway	  and	  is	  a	  tumor	  suppressor	  (123).	  Transcription	  of	  the	  caspase-­‐9	  gene	  produces	  two	  splice	  variants	  called	  caspase-­‐9a	  and	  caspase-­‐9b.	  Caspase-­‐9a	  includes	  the	  exon	  4	  cassette	  that	  consists	  of	  exons	  3,	  4,	  5,	  and	  6	  and	  is	  pro-­‐apoptotic.	  Caspase-­‐9b	  excludes	  the	  exon	  4	  cassette	  and	  is	  anti-­‐apoptotic	  (124,125).	  Exon	  3	  of	  this	  cassette	  contains	  a	  purine-­‐rich	  ESS	  to	  which	  hnRNP	  L	  binds.	  HnRNP	  L	  was	  recently	  identified	  as	  a	  target	  of	  AKT	  phosphorylation	  and	  the	  phosphorylation	  of	  hnRNP	  L	  at	  serine-­‐52	  by	  AKT	  causes	  a	  decrease	  in	  splicing	  of	  the	  exon	  4	  cassette	  and	  lowers	  the	  ratio	  of	  caspase-­‐9a	  to	  caspase-­‐9b.	  The	  lowering	  of	  the	  capsase-­‐9a/9b	  ratio	  is	  necessary	  for	  the	  tumorigenic	  ability	  of	  non-­‐small	  lung	  cancer	  cells	  (110).	  Phosphorylated	  hnRNP	  L	  competes	  against	  the	  splicing	  enhancer,	  hnRNP	  U	  for	  binding	  to	  the	  element	  (111).	  	  In	  addition	  to	  the	  well	  studied	  genes	  affected	  by	  hnRNP	  L,	  hnRNP	  L	  was	  also	  determined	  to	  affect	  a	  wide	  variety	  of	  RNAs	  that	  were	  identified	  by	  microarray	  analysis	  after	  hnRNP	  L	  depletion	  (120).	  While	  the	  function	  of	  these	  splicing	  events	  has	  yet	  to	  be	  studied,	  this	  suggests	  that	  hnRNP	  L	  may	  be	  involved	  in	  the	  regulation	  of	  a	  large	  number	  of	  splicing	  events	  beyond	  the	  examples	  presented	  above.	  	  	   	  
V.	  HnRNP	  A2/B1	  	  
A.	  Introduction	  Protein	  Structure	  	  
HnRNP	  A2/B1	  is	  part	  of	  a	  family	  of	  hnRNPs	  that	  include	  hnRNP	  A0-­‐A3	  and	  hnRNP	  B0-­‐B2.	  This	  subset	  of	  hnRNPs	  is	  known	  to	  regulate	  many	  different	  RNAs	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(32,126).	  HnRNP	  A2/B1	  are	  known	  to	  regulate	  gene	  expression	  by	  regulating	  RNA	  splicing,	  mRNA	  stability,	  transcription,	  and	  translation.	  
	   HnRNP	  A2/B1	  are	  actually	  two	  proteins.	  HnRNP	  B1	  contains	  12	  amino	  acids	  in	  its	  N-­‐terminus	  that	  are	  not	  found	  in	  hnRNP	  A2.	  The	  inclusion	  of	  these	  amino	  acids	  is	  due	  to	  an	  alternative	  splicing	  event	  (32,127).	  Commercial	  antibodies	  are	  not	  available	  that	  distinguish	  between	  these	  isoforms	  thus	  the	  literature	  likewise	  does	  not	  distinguish	  between	  them	  when	  characterizing	  their	  function.	  These	  proteins	  are	  36kDa	  and	  their	  structure	  includes	  two	  RRMs	  in	  their	  N-­‐terminus.	  The	  RRM	  domains	  of	  hnRNP	  A2/B1	  recognize	  and	  bind	  to	  the	  sequences	  UAG(purine)GA/U	  and	  UAGG	  which	  are	  similar	  to	  sequences	  to	  those	  bound	  by	  hnRNP	  A1	  (128,129).	  The	  C-­‐terminal	  ends	  of	  hnRNP	  A2/B1	  have	  a	  glycine	  rich	  region	  and	  a	  nucleocytoplasmic	  export	  signal	  (M9).	  In	  addition,	  there	  is	  an	  RGG	  (arginine,	  glycine,	  glycine)	  motif	  (32)	  that	  is	  necessary	  for	  shuttling	  between	  the	  cytoplasm	  and	  the	  nucleus.	  The	  RGG	  motif	  is	  methylated	  and	  blocking	  this	  methylation	  prevents	  the	  nuclear	  localization	  of	  hnRNP	  A2/B1	  (60).	  The	  only	  other	  posttranslational	  modification	  of	  hnRNP	  A2/B1	  that	  has	  been	  identified	  is	  phosphorylation	  by	  AKT1	  (130).	  	  
B.	  RNA	  Splicing	  and	  HnRNP	  A2/B1	  
RNA	  splicing	  is	  one	  step	  in	  gene	  expression	  that	  hnRNP	  A2/B1	  are	  known	  to	  regulate.	  HnRNP	  A2/B1	  will	  repress	  the	  splicing	  of	  exon	  2	  of	  HIV	  by	  binding	  to	  an	  ESS	  the	  exon.	  Other	  members	  of	  the	  hnRNP	  A/B	  family	  also	  bind	  to	  this	  element	  and	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repress	  the	  splicing.	  HnRNP	  A2/B1	  compete	  against	  the	  SR	  protein,	  SRSF2	  for	  binding	  to	  the	  juxtaposed	  ESE/ESS	  in	  HIV	  RNA	  and	  inhibits	  splicing	  (42,131).	  The	  splicing	  of	  the	  BRCA1	  pre-­‐mRNA	  is	  also	  regulated	  by	  hnRNP	  A2/B1,	  as	  well	  as	  hnRNP	  A1.	  The	  BRCA1	  gene	  encodes	  a	  protein	  that	  is	  necessary	  for	  DNA	  repair	  (132,133).	  	  A	  mutation	  that	  causes	  a	  switch	  from	  G	  to	  T	  in	  exon	  18	  of	  BRCA1	  causes	  skipping	  of	  this	  exon	  (134).	  The	  mutation	  creates	  an	  ESS	  element	  that	  was	  previously	  not	  there	  and	  the	  ESS	  is	  bound	  by	  the	  trans-­‐acting	  factors,	  hnRNP	  A2/B1	  and	  hnRNP	  A1.	  This	  binding	  causes	  the	  exclusion	  of	  exon	  18	  in	  the	  final	  transcript	  (135).	  Another	  example	  of	  the	  regulation	  of	  alternative	  splicing	  by	  hnRNP	  A2/B1	  is	  the	  regulation	  of	  the	  production	  of	  the	  different	  isoforms	  of	  pyruvate	  kinase	  (PK).	  Pyruvate	  kinase	  has	  2	  isoforms	  that	  are	  called	  PK-­‐M1	  and	  PK-­‐M2.	  The	  PK-­‐M1	  isoform	  arises	  from	  the	  inclusion	  of	  exon	  9	  and	  the	  exclusion	  of	  exon	  10.	  The	  PK-­‐M2	  isoform	  is	  a	  result	  of	  exon	  9	  skipping	  and	  the	  inclusion	  of	  exon	  10.	  PK-­‐M2	  is	  expressed	  at	  higher	  levels	  in	  cancer	  and	  is	  important	  for	  promoting	  tumorigenesis.	  PK-­‐M1	  is	  mainly	  expressed	  in	  tissues	  that	  are	  terminally	  differentiated	  (136-­‐139).	  	  
C.	  RNA	  Stability	  and	  HnRNP	  A2/B1	  
HnRNP	  A2/B1	  enhances	  RNA	  stability	  by	  binding	  to	  a	  U	  rich	  segment	  in	  the	  3’	  untranslated	  region	  (UTR)	  of	  collagen	  prolyl	  4	  hydroxykase	  alpha-­‐subunit	  mRNA	  (140).	  The	  stability	  of	  collagen	  prolyl	  4-­‐hydroxylase	  mRNA	  is	  also	  regulated	  by	  hnRNP	  A2/B1.	  It	  binds	  within	  a	  uridine	  rich	  element	  in	  the	  3’UTR	  of	  the	  collagen	  prolyl	  4-­‐hydroxylase	  mRNA	  and	  increases	  the	  expression	  of	  this	  mRNA	  by	  stabilizing	  it	  (140).	  HnRNP	  A2/B1	  can	  also	  inhibit	  RNA	  stability	  of	  the	  Glut-­‐I	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transporter	  mRNA.	  It	  binds	  to	  the	  3’UTR	  and	  causes	  a	  decrease	  in	  the	  mRNA	  stability	  and	  a	  decrease	  in	  the	  expression	  of	  the	  mRNA	  (141).	  It	  is	  unknown	  whether	  or	  not	  hnRNP	  A2/B1	  can	  regulate	  RNA	  stability	  outside	  of	  its	  binding	  to	  the	  3’	  UTR	  of	  mRNAs.	  	  
D.	  Regulation	  of	  Transcription	  and	  Translation	  by	  HnRNP	  A2/B1	  
	   The	  evidence	  for	  a	  role	  for	  hnRNP	  A2/B1	  in	  translation	  is	  very	  limited.	  One	  groups	  showed	  that	  hnRNP	  A2/B1	  binds	  to	  an	  A2	  response	  element	  (A2RE)	  within	  A2RE	  containing	  RNA.	  The	  binding	  of	  hnRNP	  A2/B1	  to	  the	  A2RE	  recruits	  hnRNP	  E1	  and	  this	  is	  associated	  with	  an	  inhibition	  of	  translation	  for	  that	  RNA	  (142).	  The	  only	  other	  evidence	  for	  the	  translational	  regulation	  by	  hnRNP	  A2/B1	  occurs	  when	  hnRNP	  A2/B1	  binds	  to	  CGG	  repeats	  in	  RNA	  and	  enhances	  the	  translation	  of	  RNAs	  that	  contain	  those	  repeats	  (143).	  




VI.	  Glucose-­‐6-­‐Phosphate	  Dehydrogenase	  	  
	   G6PD	  is	  part	  of	  the	  lipogenic	  enzyme	  family.	  The	  lipogenic	  enzymes	  include	  fatty	  acid	  synthase	  (FAS),	  malic	  enzyme,	  ATP-­‐citrate	  lyase,	  and	  G6PD.	  G6PD	  is	  the	  rate-­‐limiting	  enzyme	  of	  the	  pentose	  phosphate	  pathway	  that	  is	  sometimes	  referred	  to	  as	  the	  phosphogluconate	  pathway	  or	  the	  hexose	  monophosphate	  shunt.	  G6PD	  converts	  glucose-­‐6-­‐phosphate	  to	  6-­‐phosphogluconolacetone	  and	  this	  conversion	  takes	  NADP+	  and	  converts	  it	  to	  NADPH+H+.	  The	  NADPH+H+	  that	  is	  produced	  is	  used	  for	  reductive	  biochemical	  reactions	  during	  fatty	  acid	  synthesis,	  amino	  acid	  synthesis,	  cholesterol	  synthesis,	  and	  the	  reduction	  of	  glutathione	  (3,146).	  Ultimately,	  G6PD	  and	  the	  pentose	  phosphate	  pathway	  lead	  to	  the	  production	  of	  ribose-­‐5-­‐phosphate,	  which	  is	  a	  precursor	  for	  nucleotides	  and	  erythrose-­‐4-­‐phosphate,	  which	  is	  a	  precursor	  to	  many	  amino	  acids.	  The	  NADPH+H+	  that	  is	  produced	  by	  the	  reaction	  catalyzed	  by	  G6PD	  is	  required	  in	  all	  cells	  to	  help	  protect	  against	  oxidative	  stress	  and	  the	  knock	  out	  of	  G6PD	  is	  embryonic	  lethal	  (147,148).	  Mice	  that	  are	  partially	  deficient	  in	  G6PD	  have	  an	  increase	  in	  apoptosis	  in	  the	  renal	  cortex	  and	  high	  levels	  of	  albumin	  in	  their	  urine,	  which	  are	  signs	  of	  increased	  oxidative	  stress	  (149).	  G6PD	  deficiency	  affects	  nearly	  400	  million	  people	  worldwide.	  Acute	  hemolysis	  due	  to	  oxidative	  stress	  is	  the	  most	  common	  problem	  seen	  in	  people	  with	  G6PD	  deficiency	  (150)	  and	  can	  be	  precipitated	  by	  common	  infections.	  Highlighting	  the	  essentiality	  of	  G6PD	  activity,	  G6PD	  deficiency	  is	  triggered	  by	  point	  mutations	  that	  cause	  a	  decrease	  in	  its	  activity	  and	  not	  by	  frame	  shifts	  or	  large	  deletions	  that	  would	  ablate	  the	  enzyme.	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   The	  first	  step	  of	  glycolysis	  provides	  the	  glucose-­‐6-­‐phosphate	  that	  is	  a	  necessary	  substrate	  for	  G6PD.	  Glucose	  enters	  the	  cell	  and	  is	  phosphorylated	  by	  glucokinase	  in	  a	  reaction	  that	  uses	  1	  ATP	  to	  convert	  glucose	  into	  glucose-­‐6-­‐phosphate.	  The	  glucose-­‐6-­‐phosphate	  can	  be	  metabolized	  by	  either	  the	  glycolytic	  pathway	  or	  through	  the	  pentose	  phosphate	  pathway.	  Flux	  through	  glycolysis	  is	  regulated	  by	  the	  activity	  of	  6-­‐phosphofructo-­‐1-­‐kinase	  and	  involves	  multiple	  allosteric	  effectors.	  Flux	  through	  the	  pentose	  phosphate	  pathway	  is	  regulated	  by	  G6PD,	  which	  changes	  in	  its	  activity	  are	  predominantly	  regulated	  by	  changes	  in	  its	  amount.	  	  
	   The	  pentose	  phosphate	  pathway	  provides	  a	  critical	  role	  in	  fatty	  acid	  synthesis	  in	  lipogenic	  tissues	  such	  as	  the	  liver.	  The	  NADPH+H+	  that	  is	  produced	  by	  the	  enzymes	  G6PD	  and	  6-­‐phosphogluconate	  dehydrogenase	  of	  the	  pentose	  phosphate	  pathway	  provide	  approximately	  half	  of	  the	  NADPH+H+	  needed	  for	  fatty	  acid	  synthesis,	  while	  the	  malic	  enzyme	  reaction	  provides	  the	  other	  half	  (146).	  	  Carbon	  substrates	  for	  fatty	  acid	  synthesis	  are	  derived	  from	  excess	  dietary	  carbohydrate	  that	  is	  converted	  from	  glucose	  to	  citrate	  via	  glycolysis	  and	  the	  TCA	  cycle.	  Citrate	  exits	  the	  mitochondria	  via	  the	  citrate	  shuttle	  and	  is	  converted	  into	  oxaloacetate	  and	  acetyl-­‐CoA	  in	  the	  cytoplasm.	  In	  order	  to	  synthesize	  fatty	  acids	  the	  acetyl-­‐CoA	  must	  be	  converted	  to	  malonyl-­‐CoA	  via	  acetyl-­‐CoA	  carboxylase.	  The	  remaining	  reactions	  of	  fatty	  acid	  synthesis	  are	  carried	  out	  by	  fatty	  acid	  synthase.	  Fatty	  acid	  synthase	  is	  a	  large	  dimer	  that	  has	  7	  different	  catalytic	  activities.	  The	  reduction	  reactions	  of	  fatty	  acid	  synthase	  (Fig	  4)	  require	  NADPH+H+	  and	  14	  molecules	  of	  NADPH	  +	  H+	  are	  used	  in	  the	  production	  of	  1	  molecule	  of	  palmitate.	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These	  reactions	  are	  essential	  for	  the	  productions	  of	  fatty	  acids.	  After	  one	  round	  of	  the	  reactions	  1-­‐4	  (Fig	  4),	  the	  acyl-­‐ACP	  re-­‐enters	  at	  reaction	  1	  where	  it	  takes	  the	  place	  of	  acetyl-­‐	  CoA	  and	  receives	  carbons	  from	  malonyl-­‐ACP,	  which	  extends	  the	  carbon	  chain	  of	  the	  acyl-­‐ACP	  by	  2	  carbons	  as	  the	  reactions	  1-­‐4	  repeat.	  This	  cycle	  of	  reactions	  where	  2	  carbons	  are	  added	  per	  cycle	  of	  reactions	  1-­‐4	  repeats	  until	  palmitate	  is	  produced.	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synthesis	  of	  lipogenic	  enzymes	  and	  this	  regulation	  occurs	  at	  pre-­‐translational	  level.	  G6PD	  follows	  this	  same	  pattern	  of	  regulation	  of	  the	  enzymes	  in	  this	  pathway.	  Refeeding	  after	  starvation	  causes	  at	  least	  a	  12-­‐fold	  increase	  in	  the	  accumulation	  of	  G6PD	  mRNA	  (11,13).	  In	  addition	  to	  starvation	  and	  refeeding,	  mice	  fed	  a	  diet	  that	  contains	  6%	  polyunsaturated	  fat	  had	  a	  80%	  decrease	  in	  the	  expression	  of	  G6PD	  mRNA,	  compared	  to	  mice	  fed	  a	  diet	  containing	  only	  1%	  polyunsaturated	  fat	  (11).	  Primary	  rat	  hepatocytes	  have	  been	  used	  to	  identify	  dietary	  signaling	  hormones	  or	  metabolites	  that	  can	  regulate	  G6PD	  expression.	  Primary	  rat	  hepatocytes	  that	  were	  treated	  with	  insulin	  to	  mimic	  the	  fed	  state	  also	  had	  an	  increase	  in	  the	  expression	  of	  G6PD	  mRNA.	  Glucagon,	  a	  hormone	  secreted	  during	  the	  starved	  state	  does	  not	  regulate	  G6PD	  expression	  (151,152).	  Primary	  rat	  hepatocytes	  treated	  with	  polyunsaturated	  fatty	  acids	  to	  mimic	  starvation-­‐induced	  lipolysis	  or	  to	  reflect	  the	  increase	  in	  circulating	  fatty	  acid	  due	  to	  a	  diet	  enriched	  in	  polyunsaturated	  fat	  had	  a	  40-­‐60%	  decrease	  in	  the	  insulin-­‐induced	  increase	  in	  the	  expression	  of	  G6PD	  mRNA	  (153,154).	  The	  inhibition	  of	  insulin-­‐induced	  expression	  of	  G6PD	  mRNA	  by	  polyunsaturated	  fatty	  acids	  occurs	  due	  to	  the	  activation	  of	  p38	  MAP.	  The	  activation	  of	  p38	  MAP	  kinase	  coincides	  with	  the	  phosphorylation	  of	  IRS-­‐1	  at	  the	  ser-­‐307	  and	  the	  inhibition	  of	  the	  insulin-­‐induced	  increase	  in	  G6PD	  mRNA	  (155).	  	   Most	  of	  the	  lipogenic	  enzymes	  are	  regulated	  by	  changes	  the	  rate	  of	  transcription	  of	  their	  genes	  in	  response	  to	  dietary	  signals.	  Dietary	  signals	  include	  hormones,	  like	  insulin	  and	  glucagon,	  and	  dietary	  molecules	  like	  glucose	  and	  fatty	  acids.	  Unlike	  the	  other	  lipogenic	  enzymes	  whose	  expression	  is	  regulated	  by	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transcriptional	  changes,	  transcriptional	  activity	  of	  the	  G6PD	  gene	  is	  unchanged	  following	  dietary	  manipulation.	  In	  addition	  to	  transcription,	  polyadenylation	  is	  not	  altered	  by	  dietary	  manipulation	  (10,13,153).	  The	  expression	  of	  G6PD	  mRNA	  is	  regulated	  at	  a	  posttranscriptional	  step	  due	  to	  changes	  in	  the	  rate	  of	  pre-­‐mRNA	  splicing	  (3,11,13).	  Starvation,	  a	  diet	  rich	  in	  polyunsaturated	  fatty	  acids,	  and	  treatment	  of	  rat	  hepatocytes	  with	  arachidonic	  acid	  inhibit	  pre-­‐mRNA	  splicing	  and	  cause	  an	  increase	  in	  intron	  retention	  around	  exon	  12.	  The	  increase	  in	  intron	  retention	  leads	  to	  degradation	  of	  the	  incompletely	  spliced	  transcript	  and	  prevents	  the	  accumulation	  of	  mature	  mRNA	  that	  can	  be	  translated	  into	  protein	  (153).	  	  We	  hypothesized	  that	  nutrients	  regulated	  the	  splicing	  of	  G6PD	  mRNA,	  via	  a	  cis-­‐acting	  element	  in	  the	  primary	  transcript.	  To	  identify	  this	  element,	  various	  reporter	  constructs	  were	  constructed	  that	  contained	  the	  CMV	  promoter	  to	  drive	  the	  transcription	  and	  progressive	  deletions	  of	  the	  G6PD	  gene.	  These	  reporters	  were	  transfected	  into	  primary	  rat	  hepatocytes	  and	  the	  affects	  insulin	  or	  insulin	  plus	  arachidonic	  acid	  on	  the	  expression	  of	  the	  reporter	  mRNA	  was	  measured.	  Expression	  of	  the	  mRNA	  from	  these	  reporters	  was	  regulated	  by	  insulin	  and	  polyunsaturated	  fatty	  acid	  until	  exon	  12	  was	  deleted	  (153,156).	  In	  order	  to	  characterize	  the	  location	  of	  the	  regulatory	  element	  in	  exon	  12,	  separate	  G6PD	  reporters	  were	  made	  that	  contain	  block	  mutations	  within	  exon	  12.	  The	  block	  mutations	  were	  10	  nucleotides	  (AAGCATGCAA)	  in	  length.	  A	  total	  of	  9	  reporters	  were	  constructed	  to	  span	  the	  93-­‐	  nucleotide	  exon.	  Again,	  these	  reporters	  were	  transfected	  into	  primary	  rat	  hepatocytes	  and	  the	  effects	  of	  insulin	  or	  insulin	  plus	  arachidonic	  acid	  on	  the	  accumulation	  of	  the	  reporter	  mRNA	  were	  measured.	  When	  nucleotides	  43-­‐72	  of	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exon	  12	  were	  mutated	  by	  the	  block	  mutations,	  arachidonic	  acid	  treatment	  of	  rat	  hepatocytes	  no	  longer	  inhibited	  the	  expression	  of	  these	  reporters.	  Furthermore,	  addition	  of	  exon	  12	  onto	  a	  heterologous	  gene,	  β-­‐galactosidase,	  resulted	  in	  inhibition	  of	  the	  expression	  of	  this	  construct	  by	  arachidonic	  acid	  (153,156).	  Thus,	  a	  regulatory	  element	  within	  nucleotides	  43-­‐72	  of	  exon	  12	  is	  involved	  in	  nutritional	  regulation	  of	  G6PD	  expression.	  	  An	  in	  vitro	  splicing	  assay	  was	  used	  to	  further	  characterize	  the	  functional	  consequence	  of	  the	  regulatory	  element.	  RNA	  substrates	  that	  contain	  exon	  12	  or	  lack	  exon	  12	  were	  transcribed	  in	  vitro	  with	  32P-­‐labeled	  CTP.	  The	  labeled	  RNA	  substrates	  were	  incubated	  with	  HeLa	  nuclear	  extracts	  that	  contain	  all	  the	  proteins	  needed	  for	  the	  splicing	  reaction.	  Constructs	  that	  lack	  exon	  12,	  which	  includes	  RNA	  substrates	  containing	  exon8-­‐intron8-­‐exon	  9	  or	  exon	  10-­‐intron	  10-­‐exon	  11	  undergo	  splicing	  in	  the	  HeLa	  nuclear	  extracts.	  In	  contrast	  to	  the	  constructs	  that	  could	  be	  spliced,	  any	  of	  the	  RNA	  substrates	  that	  contain	  exon	  12	  were	  unable	  to	  be	  spliced	  in	  HeLa	  nuclear	  extracts	  (156).	  The	  RNA	  substrates	  that	  contain	  exon	  12	  either	  in	  its	  native	  context	  (exon	  11-­‐intron	  11-­‐exon	  12)	  or	  in	  a	  heterologous	  context	  (exon	  10-­‐intron	  10-­‐	  exon	  12)	  would	  not	  splice.	  In	  addition	  to	  the	  in	  vitro	  splicing	  assays,	  spliceosome	  assembly	  assays	  were	  used	  to	  determine	  how	  the	  regulatory	  element	  affects	  the	  steps	  in	  splicing	  catalysis.	  The	  different	  complexes	  that	  form	  during	  spliceosomal	  assembly	  can	  be	  visualized	  following	  polyacrylamide	  gel	  separation	  due	  to	  their	  different	  sizes	  (see	  Fig	  2).	  The	  early	  complexes	  that	  form	  are	  H	  and	  E,	  which	  are	  smaller,	  less	  complex,	  and	  migrate	  faster	  in	  the	  gel.	  The	  later	  complexes	  that	  form,	  like	  A,	  B	  and	  C,	  are	  larger	  and	  more	  complex,	  which	  causes	  them	  to	  migrate	  slower	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in	  the	  gel.	  The	  regulatory	  element	  in	  exon	  12	  decreases	  the	  formation	  of	  the	  A	  complex	  and	  completely	  inhibits	  the	  formation	  of	  the	  B	  and	  C	  complexes.	  This	  indicates	  that	  the	  regulatory	  element	  represses	  the	  binding	  of	  U2	  snRNP	  to	  the	  intron,	  as	  the	  A	  complex	  requires	  the	  binding	  of	  this	  protein	  (156).	  Taken	  together,	  the	  in	  vitro	  splicing	  assays	  and	  spliceosomal	  assembly	  assays	  have	  identified	  an	  ESS	  within	  nucleotides	  43-­‐72	  of	  exon	  12	  that	  inhibits	  the	  splicing	  of	  exon	  12.	  The	  identification	  of	  a	  cis-­‐acting	  ESS	  lead	  to	  the	  search	  for	  potential	  trans-­‐
acting	  factors	  that	  bind	  to	  the	  ESS	  and	  inhibit	  RNA	  splicing.	  UV	  crosslinking	  was	  one	  technique	  used	  to	  determine	  what	  possible	  factors	  may	  bind	  to	  the	  ESS	  and	  are	  potentially	  necessary	  for	  the	  splicing	  inhibition	  of	  G6PD.	  The	  oligonucleotides	  that	  span	  nucleotides	  65-­‐79	  and	  50-­‐79	  of	  exon	  12	  were	  incubated	  with	  liver	  nuclear	  extracts	  from	  starved	  and	  refed	  mice.	  UV	  crosslinking	  revealed	  bands	  at	  60kDa	  and	  37kDa	  that	  bound	  to	  the	  regulatory	  element.	  In	  addition	  to	  UV	  crosslinking,	  RNA	  affinity	  experiments	  were	  used	  to	  purify	  the	  proteins	  in	  these	  complexes.	  The	  60kDa	  band	  was	  determined	  to	  be	  hnRNP	  K	  and	  hnRNP	  L	  and	  the	  37kDA	  band	  was	  determined	  to	  be	  hnRNP	  A2/B1	  by	  liquid	  chromatography-­‐tandem	  mass	  spectrometry.	  Interestingly,	  binding	  of	  hnRNPs	  K,	  L	  and	  A2/B1	  to	  the	  probe	  that	  spans	  nucleotides	  50-­‐79	  was	  increased	  60-­‐70%	  when	  nuclear	  extracts	  were	  made	  from	  the	  livers	  of	  starved	  mice	  as	  compared	  to	  the	  livers	  of	  mice	  that	  were	  refed	  (14,156).	  Based	  on	  this	  data,	  the	  hnRNPs	  K,	  L,	  and	  A2/B1	  may	  be	  the	  trans-­‐acting	  factors	  that	  bind	  to	  the	  ESS	  to	  inhibit	  splicing	  of	  G6PD,	  as	  they	  bound	  more	  to	  the	  ESS	  during	  starvation.	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In	  addition	  to	  the	  ESS,	  the	  regulatory	  element	  contains	  a	  second	  cis-­‐acting	  element	  that	  is	  required	  for	  the	  nutrient	  regulation	  of	  the	  splicing	  of	  G6PD	  mRNA.	  The	  first	  piece	  of	  data	  to	  support	  that	  exon	  12	  contains	  another	  cis-­‐acting	  element	  that	  is	  found	  within	  the	  regulatory	  element	  was	  the	  in	  vitro	  splicing	  assay.	  	  When	  the	  regulatory	  element	  was	  removed	  from	  the	  exon	  11-­‐intron-­‐11-­‐exon-­‐12	  substrate	  used	  in	  the	  in	  vitro	  splicing	  assay,	  splicing	  was	  still	  inhibited	  and	  if	  this	  region	  only	  contained	  an	  ESS	  then	  the	  substrate	  should	  be	  able	  to	  be	  splice	  (156).	  This	  data	  suggests	  that	  the	  regulatory	  element	  also	  contains	  an	  ESE.	  More	  recent	  evidence	  shows	  that	  exon	  12	  does	  in	  fact	  contain	  an	  ESE	  and	  that	  a	  trans-­‐acting	  factor	  that	  enhances	  the	  splicing	  of	  G6PD	  binds	  to	  the	  ESE.	  We	  identified	  that	  a	  SR	  protein,	  SRSF3	  binds	  to	  the	  exon	  12	  regulator	  element	  by	  using	  RNA	  affinity	  assays.	  Mouse	  liver	  nuclear	  extracts	  from	  mice	  that	  were	  either	  starved	  or	  refed	  were	  incubated	  with	  an	  oligonucleotide	  that	  spans	  the	  regulatory	  element	  in	  exon	  12.	  Interestingly,	  the	  binding	  of	  SRSF3	  was	  enhanced	  in	  the	  extracts	  from	  the	  refed	  mice.	  Treating	  primary	  rat	  hepatocytes	  with	  insulin	  to	  mimic	  refeeding	  also	  showed	  that	  there	  was	  an	  increase	  the	  expression	  of	  phosphorylated	  SR	  proteins,	  which	  included	  SRSF3.	  Depletion	  of	  SRSF3	  by	  siRNA	  in	  HepG2	  cells	  that	  stably	  express	  a	  G6PD	  reporter	  identified	  that	  SRSF3	  acts	  to	  enhance	  the	  expression	  of	  this	  reporter	  and	  the	  endogenous	  G6PD	  gene.	  Additionally,	  using	  RNA	  immunoprecipitation	  (RIP),	  the	  binding	  of	  to	  SRSF3	  the	  regulatory	  element	  was	  detected	  in	  mouse	  liver.	  SRSF3	  does	  bind	  to	  the	  regulatory	  element	  in	  whole	  mouse	  liver	  and	  refeeding	  enhances	  the	  binding	  of	  SRSF3.	  The	  increase	  in	  the	  binding	  of	  SRSF3	  corresponds	  with	  an	  increase	  in	  the	  expression	  of	  G6PD	  mRNA	  (157).	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Chapter	  2	  
Starvation	  actively	  inhibits	  splicing	  of	  glucose-­‐6-­‐phosphate	  dehydrogenase	  
mRNA	  via	  a	  bifunctional	  ESE/ESS	  element	  bound	  by	  hnRNP	  K	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Regulated	  expression	  of	  glucose-­‐6-­‐phosphate	  dehydrogenase	  (G6PD)	  is	  due	  to	  changes	  in	  the	  rate	  of	  pre-­‐mRNA	  splicing	  and	  not	  changes	  in	  its	  transcription.	  Starvation	  alters	  pre-­‐mRNA	  splicing	  by	  decreasing	  the	  rate	  of	  intron	  removal,	  leading	  to	  intron	  retention	  and	  a	  decrease	  in	  the	  accumulation	  of	  mature	  mRNA.	  A	  regulatory	  element	  within	  exon	  12	  of	  G6PD	  pre-­‐mRNA	  controls	  splicing	  efficiency.	  	  Starvation	  caused	  an	  increase	  in	  the	  expression	  of	  heterogeneous	  nuclear	  ribonucleoprotein	  (hnRNP)	  K	  protein	  and	  this	  increase	  coincided	  with	  the	  increase	  in	  the	  binding	  of	  hnRNP	  K	  to	  the	  regulatory	  element	  and	  a	  decrease	  in	  the	  expression	  of	  G6PD	  mRNA.	  	  HnRNP	  K	  bound	  to	  two	  C-­‐rich	  motifs	  forming	  an	  ESS	  within	  exon	  12.	  	  Overexpression	  of	  hnRNP	  K	  decreased	  the	  splicing	  and	  expression	  of	  G6PD	  mRNA,	  while	  siRNA-­‐mediated	  depletion	  of	  hnRNP	  K	  caused	  an	  increase	  in	  the	  splicing	  and	  expression	  of	  G6PD	  mRNA.	  Binding	  of	  hnRNP	  K	  to	  the	  regulatory	  element	  was	  enhanced	  in	  vivo	  by	  starvation	  coinciding	  with	  a	  decrease	  in	  G6PD	  mRNA.	  	  HnRNP	  K	  binding	  to	  the	  C-­‐rich	  motifs	  blocked	  binding	  of	  serine-­‐arginine	  rich,	  splicing	  factor	  3	  (SRSF3),	  a	  splicing	  enhancer.	  	  Thus	  hnRNP	  K	  is	  a	  nutrient	  regulated	  splicing	  factor	  responsible	  for	  the	  inhibition	  of	  the	  splicing	  of	  G6PD	  during	  starvation.	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1.	  	  INTRODUCTION	  
Maintenance	  of	  energy	  homeostasis	  throughout	  the	  body	  is	  achieved	  by	  balancing	  the	  use	  of	  dietary	  energy	  to	  meet	  immediate	  needs	  and	  the	  storage	  of	  excess	  energy	  for	  use	  in	  the	  absence	  of	  dietary	  intake.	  	  A	  key	  pathway	  involved	  in	  this	  process	  is	  lipogenesis,	  by	  which	  excess	  energy	  in	  the	  form	  of	  carbohydrate	  is	  converted	  to	  triacylglycerol	  for	  storage	  in	  adipose	  tissue	  and	  as	  such	  this	  pathway	  is	  highly	  active	  and	  regulated	  in	  adipose	  tissue	  and	  liver.	  	  The	  enzymes	  involved	  in	  lipogenesis,	  ATP-­‐citrate	  lyase,	  malic	  enzyme,	  fatty	  acid	  synthase,	  glucose-­‐6-­‐phosphate	  dehydrogenase	  (G6PD)2,	  and	  acetyl-­‐CoA	  carboxylase	  increase	  in	  amount	  during	  consumption	  of	  high-­‐carbohydrate	  diets	  in	  order	  to	  increase	  a	  cell’s	  capacity	  for	  lipogenesis;	  however,	  in	  response	  to	  starvation	  the	  amount	  of	  these	  proteins	  is	  decreased	  [1].	  	  Dietary	  regulation	  of	  these	  proteins	  is	  controlled	  by	  both	  dietary	  nutrients	  and	  by	  changes	  in	  the	  amounts	  of	  key	  regulatory	  hormones	  such	  as	  insulin	  and	  glucagon.	  	  Regulation	  of	  most	  of	  the	  lipogenic	  enzymes	  is	  primarily	  through	  changes	  the	  transcriptional	  activity	  of	  their	  genes	  [1].	  	  G6PD	  is	  an	  exception	  in	  this	  family.	  	  Nutrient	  and	  hormonal	  regulation	  of	  G6PD	  expression	  is	  exclusively	  by	  changes	  in	  the	  degree	  of	  splicing	  of	  its	  mRNA	  [2,	  3].	  	  
                                                
2 CMV, cytomegalovirus; EMSA, electrophoretic mobility shift assay; ESE, exonic 
splicing enhancer; ESS, exonic splicing silencer; G6PD, glucose-6-phosphate 
dehydrogenase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GST, glutathione 
S-transferase; HEXTM, hexachlorofluorescein; hnRNP, heterogeneous nuclear 
ribonucleoprotein; RFP, red fluorescent protein; RIP, RNA immunoprecipitation; SRSF3, 




RNA	  splicing	  is	  an	  essential	  step	  in	  gene	  expression	  that	  joins	  together	  the	  exons	  in	  the	  nascent	  transcript	  [4].	  	  Splicing	  is	  a	  highly	  regulated	  process	  such	  that	  a	  single	  transcript	  can	  generate	  multiple	  mature	  mRNA	  via	  a	  process	  called	  alternative	  splicing.	  	  Evidence	  from	  global	  RNA	  sequencing	  indicates	  that	  alternative	  splicing	  is	  widespread	  and	  crucial	  for	  the	  proper	  function	  and	  fate	  of	  a	  cell	  [5-­‐8].	  	  In	  addition	  to	  alternative	  exon	  inclusion,	  the	  recognition	  and	  splicing	  of	  constitutive	  exons	  that	  are	  always	  present	  in	  the	  mature	  mRNA	  is	  regulated.	  	  Regulation	  of	  constitutive	  exon	  splicing	  can	  result	  in	  retained	  introns,	  which	  can	  trigger	  degradation	  of	  the	  mRNA	  presumably	  through	  nonsense-­‐mediated	  decay	  [9].	  This	  latter	  category	  is	  the	  type	  of	  alternative	  splicing	  that	  regulates	  expression	  of	  G6PD	  [3].	  	  Alternative	  splicing	  and	  intron	  retention	  share	  regulatory	  mechanisms	  that	  involve	  the	  binding	  of	  splicing	  regulatory	  proteins	  to	  cis-­‐acting	  elements	  within	  the	  mRNA.	  	  Within	  exons,	  these	  sequences	  are	  called	  exonic	  splicing	  enhancers	  (ESE)	  or	  exonic	  splicing	  silencers	  (ESS).	  	  Two	  protein	  families	  that	  include	  serine-­‐arginine	  rich	  (SR)	  proteins	  and	  heterogeneous	  nuclear	  ribonucleoproteins	  (hnRNPs)	  are	  known	  to	  function	  as	  trans-­‐acting	  factors,	  which	  regulate	  splicing	  through	  binding	  to	  the	  ESE	  and	  ESS	  elements,	  respectively	  [10-­‐15].	  As	  such,	  these	  proteins	  contain	  RNA	  recognition	  motifs	  by	  which	  they	  can	  bind	  to	  the	  pre-­‐mRNA.	  	  
	  
The	  mechanisms	  by	  which	  SR	  proteins	  and	  hnRNPs	  respond	  to	  environmental	  and	  cellular	  cues	  are	  only	  now	  emerging.	  	  Serine	  phosphorylation	  of	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SR	  proteins	  is	  a	  primary	  mechanism	  regulating	  their	  activity,	  and	  phosphorylation	  is	  associated	  with	  enhanced	  splicing	  of	  the	  SR	  protein	  targets	  [16].	  	  In	  contrast,	  hnRNPs	  act	  both	  as	  enhancers	  or	  inhibitors	  of	  mRNA	  splicing	  as	  well	  as	  regulate	  other	  steps	  in	  gene	  expression	  [17-­‐19].	  	  Many	  hnRNPs	  can	  be	  phosphorylated,	  methylated	  on	  arginines	  and	  modified	  by	  sumoylation	  [20,	  21].	  	  Thus,	  hnRNPs	  could	  be	  candidates	  for	  nutritional	  regulation	  of	  splicing.	  	  
	  
The	  observation	  that	  nutritional	  status	  can	  regulate	  RNA	  splicing	  has	  widespread	  implications	  for	  regulation	  of	  cellular	  function.	  	  G6PD	  provides	  a	  useful	  model	  to	  study	  splicing	  changes	  that	  occur	  in	  response	  to	  nutritional	  status	  because	  this	  is	  the	  sole	  mechanism	  regulating	  the	  accumulation	  of	  its	  mRNA.	  	  In	  mouse	  liver,	  accumulation	  of	  spliced	  G6PD	  mRNA	  occurs	  following	  consumption	  of	  a	  high	  carbohydrate,	  low-­‐fat	  diet.	  	  Conversely,	  the	  amount	  of	  mature	  mRNA	  is	  decreased	  significantly	  by	  starvation	  or	  consumption	  of	  a	  diet	  high	  in	  polyunsaturated	  fatty	  acids	  [3,	  22,	  23].	  The	  decrease	  in	  splicing	  of	  the	  nascent	  transcript	  is	  associated	  with	  a	  decrease	  in	  the	  removal	  of	  introns	  surrounding	  exon	  12	  of	  the	  G6PD	  mRNA	  and	  G6PD	  pre-­‐mRNA	  containing	  these	  retained	  introns	  accumulates	  prior	  to	  its	  degradation	  [23].	  Exon	  12	  contains	  the	  regulatory	  elements	  that	  are	  necessary	  for	  the	  nutrient	  regulation	  of	  splicing,	  which	  include	  both	  an	  ESS	  and	  an	  ESE	  [3,	  24].	  	  The	  SR	  protein,	  SR	  splicing	  factor	  3	  (SRSF3)	  binds	  to	  the	  ESE	  within	  exon	  12,	  thus	  increasing	  splicing	  of	  G6PD	  pre-­‐mRNA	  during	  refeeding	  [24].	  The	  increase	  in	  splicing	  of	  G6PD	  pre-­‐mRNA	  results	  in	  accumulation	  of	  mature	  mRNA	  and	  ultimately	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more	  G6PD	  enzyme	  activity.	  	  The	  question	  remains,	  is	  inefficient	  splicing	  of	  exon	  12	  the	  default	  state	  to	  which	  liver	  reverts	  during	  starvation?	  	  In	  addition	  to	  SRSF3,	  we	  identified	  3	  members	  of	  the	  hnRNP	  family	  of	  proteins,	  K,	  L	  and	  A2/B1	  that	  bind	  to	  this	  element	  in	  vitro	  [25].	  In	  the	  present	  report,	  we	  test	  the	  hypothesis	  that	  hnRNP	  K,	  L	  and/or	  A2/B1	  inhibit	  splicing	  of	  the	  G6PD	  mRNA	  and	  are	  involved	  in	  the	  inhibition	  of	  G6PD	  expression	  during	  starvation.	  	  We	  found	  that	  expression	  of	  hnRNP	  K	  increased	  during	  starvation,	  which	  resulted	  in	  an	  increase	  in	  its	  binding	  to	  the	  ESS	  with	  exon	  12.	  	  HnRNP	  K	  inhibited	  splicing	  of	  the	  G6PD	  nascent	  transcript	  as	  well	  as	  a	  splicing	  reporter	  that	  contains	  the	  exon	  12	  regulatory	  element.	  	  Conversely,	  siRNA-­‐mediated	  depletion	  of	  hnRNP	  K	  resulted	  in	  increased	  splicing	  of	  the	  G6PD	  pre-­‐mRNA.	  	  Finally,	  hnRNP	  K	  and	  SRSF3	  bind	  to	  the	  same	  sequences	  within	  the	  regulatory	  element	  and	  do	  so	  in	  a	  mutually	  exclusive	  manner.	  	  We	  propose	  that	  hnRNP	  K	  is	  a	  nutrient-­‐regulated	  silencer	  of	  RNA	  splicing.	  
	  
2.	  MATERIAL	  AND	  METHODS	  
	   All	  animal	  experiments	  were	  conducted	  in	  conformity	  with	  the	  Public	  Health	  Service	  policy	  on	  Human	  Care	  and	  Use	  of	  Laboratory	  Animals,	  additionally	  the	  Institutional	  Animal	  Care	  and	  Use	  Committee	  of	  the	  Division	  of	  Laboratory	  Animal	  Resources	  at	  West	  Virginia	  University	  approved	  all	  experimental	  procedures.	  	  
	  
2.1.	  	  RNA	  Electrophoretic	  Mobility	  Shift	  Assay	  (EMSA)	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   The	  RNA	  EMSA	  protocol	  is	  a	  modification	  of	  existing	  methods	  [26,	  27].	  Briefly,	  100	  fmol	  of	  a	  5’-­‐hexachlorofluorescein	  (HEXTM)	  labelled-­‐RNA	  probe	  (IDT)	  corresponding	  to	  nucleotides	  (nt)	  50-­‐84	  of	  Exon	  12	  was	  mixed	  with	  92	  ng	  of	  purified	  recombinant	  FLAG-­‐tagged	  hnRNP	  K	  (Origene)	  in	  1X	  binding	  buffer	  (10	  mM	  Tris	  pH	  7.3,	  1	  mM	  MgCl2,	  20	  mM	  KCl,	  1	  mM	  DTT,	  1	  U	  of	  SuperRNasin	  (Ambion))	  plus/minus	  unlabeled	  competitor	  oligonucleotides	  (0,	  1	  pmol,	  2.5	  pmol,	  5	  pmol,	  7.5pmol,	  10	  pmol;	  IDT)	  in	  a	  total	  reaction	  volume	  of	  20	  μL.	  The	  reactions	  were	  incubated	  for	  30	  min	  at	  room	  temperature.	  	  Supershift	  reactions	  received	  1	  µg	  of	  anti-­‐hnRNP	  K	  (3C2,	  Abcam)	  20	  min	  into	  the	  initial	  binding	  reaction	  and	  the	  reaction	  proceeded	  another	  10	  min.	  The	  samples	  were	  loaded	  onto	  a	  pre-­‐running	  5%	  native	  polyacrylamide	  gel.	  The	  gel	  was	  imaged	  directly	  on	  a	  Typhoon	  9410	  Imager	  and	  signals	  were	  quantified	  using	  ImageQuant	  TL	  software.	  RNA	  EMSAs	  involving	  competition	  between	  hnRNP	  K	  and	  SRSF3	  were	  incubated	  in	  the	  conditions	  as	  previously	  described	  [24].	  Purified	  recombinant	  FLAG-­‐tagged	  hnRNP	  K	  (Origene)	  and	  purified	  recombinant	  glutathione	  S-­‐transferase	  (GST)	  conjugated-­‐	  SRSF3	  (Abnova)	  were	  incubated	  in	  1X	  binding	  buffer	  (10	  mM	  Tris	  pH	  7.5,	  1	  mM	  MgCl2,	  100	  mM	  KCl,	  0.1	  mM	  DTT,	  5%	  glycerol;	  ref.	  25)	  in	  a	  total	  reaction	  volume	  of	  20	  μL	  with	  100	  fmol	  of	  a	  5’-­‐hexachlorofluorescein	  (HEXTM)	  labelled-­‐RNA	  probe	  (IDT)	  corresponding	  to	  nt	  50-­‐84	  of	  Exon	  12.	  Reactions	  were	  incubated	  and	  analyzed	  as	  previously	  described	  [24].	  	  
	  
2.2.	  	  Western	  analysis	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   Whole	  cell	  lysates	  [24]	  and	  nuclear	  extracts	  [25]	  were	  prepared	  as	  described.	  	  After	  gel	  electrophoresis,	  the	  proteins	  were	  transferred	  to	  PDVF	  membrane	  (Bio-­‐Rad),	  and	  probed	  with	  the	  antibodies	  as	  indicated	  in	  the	  figure	  legends.	  HnRNP	  A2/B1,	  hnRNP	  L	  and	  hnRNP	  K	  specific	  antibodies	  (Santa	  Cruz	  Biotechnology)	  and	  b-­‐tubulin	  antibody	  (Cell	  Signalling)	  were	  obtained	  from	  the	  indicated	  sources.	  	  Secondary	  antibodies	  were	  conjugated	  to	  horseradish	  peroxidase	  and	  the	  antibody	  interactions	  were	  detected	  using	  ECL	  plus	  (GE	  Healthcare)	  followed	  by	  visualization	  on	  film	  and	  a	  Typhoon	  9410	  Imager	  (GE	  Healthcare).	  Signals	  were	  quantified	  with	  ImageJ	  (NIH)	  and	  ImageQuant	  TL	  (Molecular	  Dynamics),	  respectively.	  	  To	  verify	  the	  accuracy	  of	  the	  protein	  quantitation	  in	  the	  nuclear	  extracts,	  the	  extracts	  were	  run	  on	  a	  polyacrylamide	  gel	  and	  silver	  stained.	  	  The	  overall	  intensity	  of	  the	  visualized	  bands	  was	  similar	  betweens	  starved	  and	  refed	  samples	  (data	  not	  shown).	  	  	  
	  
2.3.	  	  RNA	  isolation	  and	  measurement	  
	   Total	  cellular	  RNA	  was	  isolated	  using	  TRI	  Reagent®	  (Molecular	  Research	  Center).	  The	  total	  RNA	  was	  then	  digested	  with	  DNase	  I	  (Turbo	  DNA-­‐free,	  Invitrogen)	  according	  to	  the	  manufacture’s	  protocol.	  Specific	  RNA	  amounts	  were	  quantified	  by	  RT-­‐qPCR	  (ICYCLER,	  Bio-­‐Rad)	  using	  the	  QuantiTect	  SYBR	  Green	  kit	  (Qiagen)	  and	  primers	  listed	  in	  supplemental	  Table	  1.	  	  All	  reactions	  were	  carried	  out	  in	  duplicate	  and	  annealing	  temperatures	  for	  each	  set	  of	  primers	  were	  determined	  by	  using	  melting	  curves.	  	  The	  amount	  of	  each	  mRNA	  was	  calculated	  using	  a	  relative	  standard	  curve.	  	  All	  RNA	  samples	  were	  also	  amplified	  in	  the	  absence	  of	  reverse	  transcriptase	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to	  test	  for	  DNA	  contamination.	  	  Samples	  with	  DNA	  contamination	  were	  digested	  with	  DNase	  I	  a	  second	  time.	  
	  
2.4.	  	  HnRNP	  K	  overexpression	  and	  RNA	  reporters	  
	   HepG2	  (human	  hepatoma)	  cells	  were	  generated	  that	  stably	  express	  the	  RNA	  splicing	  reporters:	  	  Exon	  12(+)	  or	  Exon	  12(-­‐)	  (Fig.	  2)	  and	  were	  used	  for	  experiments	  testing	  the	  effect	  of	  overexpressing	  hnRNP	  K.	  	  The	  Exon	  12(+)	  reporter	  contains	  mouse	  genomic	  DNA	  comprising	  nt	  38-­‐93	  of	  exon	  12	  through	  the	  end	  of	  the	  G6PD	  gene	  as	  departed	  by	  a	  repetitive	  element,	  ligated	  to	  b-­‐galactosidase	  and	  expression	  was	  driven	  by	  the	  CMV	  promoter.	  	  The	  cells	  were	  co-­‐transfected	  with	  a	  plasmid	  expressing	  the	  neomycin	  resistance	  gene.	  	  Stable	  transformants	  were	  selected	  with	  G418	  and	  then	  clonally	  isolated	  so	  that	  all	  cells	  reflect	  a	  single	  site	  of	  insertion	  of	  the	  RNA	  reporter.	  	  The	  Exon	  12(-­‐)	  reporter	  was	  constructed	  as	  the	  Exon	  12(+)	  reporter	  but	  contains	  only	  the	  last	  8	  nt	  of	  exon	  12	  to	  preserve	  the	  5’	  splice	  site	  of	  the	  intron.	  	  One	  day	  after	  plating	  2	  X	  105	  cells	  in	  a	  6	  well	  plate,	  HepG2	  cells	  were	  transfected	  with	  3	  μg	  of	  an	  expression	  vector	  for	  hnRNP	  K	  (Origene)	  or	  a	  control	  plasmid	  that	  expressed	  red	  fluorescent	  protein	  (RFP;	  pEGFP-­‐N1,	  Clontech	  with	  RFP	  substituted	  for	  GFP;	  gift	  of	  Peter	  Stoilov)	  using	  the	  Express-­‐in	  transfection	  reagent	  (Thermo	  Scientific)	  in	  DMEM	  containing	  10%	  FBS.	  Total	  RNA	  and	  whole-­‐cell	  protein	  extracts	  were	  collected	  after	  48	  h.	  Cell	  lysates	  were	  prepared	  using	  RIPA	  buffer	  plus	  phosphatase	  and	  protease	  inhibitors	  (Thermo	  Scientific).	  The	  quantitation	  of	  spliced	  versus	  unspliced	  reporter	  RNA	  used	  RT-­‐qPCR	  and	  primers	  that	  produced	  218	  bp	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and	  119	  bp	  products,	  respectively.	  
	   To	  test	  for	  effects	  of	  hnRNP	  K	  on	  mRNA	  stability	  apart	  from	  splicing,	  HepG2	  cells	  stably	  expressing	  a	  doxycycline	  inducible	  hnRNP	  K	  (section	  2.5)	  were	  treated	  with	  doxycycline	  for	  72	  h.	  	  During	  the	  last	  24	  h	  of	  doxycycline	  treatment,	  the	  cells	  were	  transiently	  transfected	  with	  2	  µg	  of	  reporter	  plasmid	  that	  contains	  the	  CMV	  promoter,	  the	  mouse	  G6PD	  cDNA,	  and	  the	  entire	  3’-­‐end	  of	  the	  G6PD	  gene	  [23].	  	  Transfection	  was	  performed	  as	  described	  above	  and	  RNA	  and	  protein	  extracts	  were	  prepared	  24	  h	  after	  transfection.	  	  The	  accumulation	  of	  mouse	  G6PD	  mRNA	  produced	  by	  the	  reporter	  was	  measured	  with	  RT-­‐qPCR	  and	  primers	  to	  exon	  13	  of	  the	  mouse	  RNA	  (supplemental	  Table	  1)	  that	  differs	  significantly	  from	  the	  endogenous	  human	  G6PD	  mRNA.	  
	  
2.5.	  	  Isolation	  of	  chromatin-­‐associated	  RNA	  
	   The	  isolation	  of	  the	  chromatin	  fraction	  of	  nuclei	  and	  of	  the	  RNA	  in	  this	  fraction	  was	  by	  an	  existing	  protocol	  [28].	  HepG2	  cells	  were	  derived	  that	  stably	  express	  hnRNP	  K	  under	  a	  doxycycline	  inducible	  promoter.	  Cells	  (6.5	  X	  106)	  were	  plated	  in	  a	  150mm	  plate	  with	  DMEM	  containing	  10%	  FBS.	  	  Doxycycline	  (5	  μg/ml)	  was	  added	  to	  the	  cells	  one	  day	  after	  plating.	  	  Wild	  type	  HepG2	  cells	  were	  treated	  in	  the	  identical	  manner	  and	  were	  a	  control	  for	  non-­‐specific	  effects	  of	  doxycycline.	  	  After	  72	  h	  with	  doxycycline,	  chromatin-­‐associated	  RNA	  was	  collected.	  The	  quantitation	  of	  spliced	  versus	  unspliced	  RNA	  used	  RT-­‐qPCR	  with	  primers	  to	  the	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endogenous	  G6PD	  mRNA	  (Fig.	  3E).	  	  Primers	  detecting	  pre-­‐mRNA	  retaining	  intron	  11	  produced	  a	  156	  bp	  product	  and	  primers	  that	  detected	  pre-­‐mRNA	  retaining	  intron	  12	  produced	  a	  168	  bp	  product	  (supplemental	  Table	  1).	  	  
	  
2.6.	  	  SiRNA	  transfection	  
	   HepG2	  cells	  stably	  expressing	  the	  RNA	  splicing	  reporter	  Exon	  12(+)	  or	  Exon	  12(-­‐)	  were	  used	  for	  siRNA	  depletion	  of	  hnRNPs.	  One	  day	  after	  plating,	  the	  HepG2	  cells	  (3.5	  X	  105)	  were	  transfected	  with	  a	  mixture	  of	  2	  siRNAs	  (Thermo	  Scientific)	  against	  hnRNP	  K	  or	  hnRNP	  L	  (50	  nM	  each	  siRNA;	  supplemental	  Table	  1).	  	  Transfections	  were	  performed	  with	  TransIT-­‐siQUEST®	  transfection	  reagent	  (Mirus)	  in	  DMEM	  medium	  containing	  10%	  FBS.	  	  SiGENOME	  SMART	  non-­‐targeting	  siRNA	  pool	  #1	  was	  used	  as	  a	  negative	  control	  (Thermo	  Scientific).	  Total	  RNA	  and	  whole-­‐cell	  lysates	  were	  collected	  after	  48h.	  	  
	  
2.7.	  	  RNA	  Immunoprecipitation	  (RIP)	  
	   The	  RIP	  protocol	  is	  a	  modification	  of	  existing	  methods	  [29,	  30].	  	  For	  HepG2	  cells,	  the	  formaldehyde	  crosslinking	  and	  cell	  lysis	  were	  performed	  as	  previously	  described	  [24].	  Crosslinking	  was	  stopped	  by	  the	  addition	  of	  glycine	  to	  125	  mM.	  	  Following	  the	  cell	  lysis,	  lysate	  containing	  500	  µg	  of	  protein	  was	  suspended	  in	  buffer	  (1x	  PBS,	  2X	  HaltTM	  Protease	  and	  Phosphatase	  Inhibitor	  Cocktail	  and	  2U/uL	  SUPERaseInTMRNAse	  Inhibitor)	  and	  pre-­‐cleared	  with	  protein	  G	  Dynabeads	  at	  4°C	  for	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2	  h	  with	  rotation.	  A	  portion	  of	  the	  lysate	  was	  saved	  for	  the	  “input”	  sample.	  In	  a	  separate	  tube,	  protein	  G	  Dynabeads	  (Invitrogen)	  were	  washed	  twice	  with	  1x	  PBS	  +	  0.02%	  Tween	  20	  (PBS/T).	  Antibodies	  (10	  μg,	  hnRNP	  K	  (3C2),	  Abcam	  and	  normal	  mouse	  IgG,	  Millipore)	  were	  added	  to	  the	  beads	  and	  incubated	  at	  room	  temperature	  for	  2	  h	  with	  rotation.	  The	  antibody-­‐bound	  beads	  were	  washed	  three	  times	  with	  PBS/T	  and	  then	  mixed	  with	  the	  pre-­‐cleared	  lysates.	  The	  bead/lysate	  mixtures	  were	  incubated	  overnight	  at	  4°C	  with	  rotation	  and	  then	  washed	  six	  times	  with	  PBS/T.	  RNA	  bound	  to	  the	  immunoprecipitated	  proteins	  was	  released	  by	  treatment	  with	  proteinase	  K	  as	  previously	  described	  [24]	  and	  amplified	  by	  RT-­‐qPCR	  using	  the	  primers	  in	  supplemental	  Table	  1.	  Amplification	  without	  RT	  was	  used	  as	  a	  control	  for	  chromatin	  contamination.	  
For	  detection	  of	  hnRNP	  K	  binding	  to	  the	  regulatory	  element	  in	  whole	  liver,	  8-­‐10	  week	  old	  male	  C57BL/6J	  (The	  Jackson	  Laboratory)	  were	  fasted	  for	  18h	  or	  were	  fasted	  for	  18h,	  and	  then	  refed	  a	  low-­‐fat,	  high-­‐carbohydrate	  diet	  (Basal	  Mix	  TD.00235,	  Harlan	  Laboratories;	  supplemented	  with	  1%	  safflower	  oil)	  for	  12	  h.	  The	  livers	  were	  removed	  and	  processed	  as	  previously	  described	  [24].	  All	  subsequent	  immunoprecipitations	  and	  amplifications	  of	  bound	  RNA	  were	  done	  as	  described	  for	  HepG2	  cells.	  
	  
2.8.	  	  Statistical	  Analysis	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   All	  statistical	  comparisons	  were	  made	  using	  the	  student’s	  t-­‐test.	  Significance	  is	  defined	  as	  p<0.05.	  	  
	  
3.	  	  RESULTS	  
3.1.	  	  Starvation	  increases	  hnRNP	  K	  protein	  levels	  in	  vivo	  
	   To	  address	  the	  hypothesis	  that	  hnRNPs	  are	  starvation-­‐induced	  splicing	  silencers,	  we	  measured	  the	  change	  in	  their	  expression	  in	  the	  livers	  of	  mice	  subjected	  to	  mild	  starvation.	  	  Starvation	  caused	  a	  3-­‐fold	  increase	  in	  the	  expression	  of	  hnRNP	  K	  protein	  as	  compared	  mice	  that	  were	  refed	  a	  high	  carbohydrate	  diet	  after	  a	  period	  of	  starvation	  (Fig.	  1A).	  	  	  Antibodies	  to	  hnRNP	  L	  and	  hnRNP	  A2/B1	  each	  detect	  2	  bands	  for	  the	  respective	  proteins.	  	  The	  reason	  for	  the	  doublet	  is	  not	  known.	  	  Regardless,	  expression	  of	  hnRNP	  L	  and	  A2/B1	  did	  not	  change	  between	  starved	  and	  refed	  livers	  (Fig.	  1B).	  	  Because	  hnRNP	  A2/B1	  shuttles	  from	  the	  nucleus	  to	  the	  cytoplasm	  [31],	  we	  specifically	  measured	  its	  abundance	  in	  nuclear	  extracts	  to	  reflect	  the	  cellular	  pool	  in	  which	  the	  amount	  of	  this	  protein	  would	  be	  expected	  to	  change.	  Again,	  there	  was	  no	  change	  in	  the	  expression	  of	  hnRNP	  A2/B1	  in	  the	  nucleus	  comparing	  the	  expression	  in	  10	  different	  mice	  (Fig.	  1C).	  To	  control	  for	  protein	  quantitation,	  polyacrylamide	  gels	  of	  the	  nuclear	  extracts	  were	  silver-­‐stained;	  overall	  protein	  abundance	  was	  similar	  between	  the	  dietary	  treatments.	  	  Thus	  abundance	  of	  hnRNP	  K	  is	  increased	  by	  a	  dietary	  paradigm	  that	  results	  in	  decreased	  splicing	  of	  the	  G6PD	  mRNA	  and	  decreased	  expression	  of	  the	  G6PD	  enzyme	  [3,	  22,	  23].	  	  The	  fact	  that	  hnRNP	  A2/B1	  does	  not	  change	  in	  abundance	  during	  starvation	  coupled	  with	  our	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previous	  data	  that	  hnRNP	  A2/B1	  binds	  to	  multiple	  exons	  in	  the	  G6PD	  gene	  (Griffith	  and	  Salati,	  data	  not	  shown)	  argue	  that	  it	  does	  not	  play	  a	  major	  role	  in	  starvation	  induced	  silencing	  of	  G6PD	  expression.	  	  Thus,	  we	  have	  not	  pursued	  further	  experiments	  with	  this	  protein.	  
	  
3.2.	  	  SiRNA	  depletion	  of	  hnRNP	  K	  but	  not	  hnRNP	  L	  increases	  the	  splicing	  of	  G6PD	  
	   SiRNA-­‐mediated	  depletions	  of	  hnRNP	  K	  and	  hnRNP	  L	  were	  used	  to	  test	  their	  functional	  significance	  on	  the	  expression	  of	  G6PD	  mRNA.	  Two	  HepG2	  cell	  lines	  were	  developed	  that	  stably	  expressed	  splicing	  reporters	  either	  with	  (+)	  or	  without	  (-­‐)	  exon	  12	  ligated	  to	  the	  heterologous	  gene,	  β-­‐galactosidase.	  	  The	  Exon	  12(+)	  reporter	  permits	  the	  evaluation	  of	  changes	  in	  the	  splicing	  and	  the	  overall	  expression	  of	  the	  reporter	  mRNA	  driven	  solely	  by	  the	  splicing	  regulatory	  element	  within	  exon	  12	  and	  not	  affected	  by	  regulatory	  elements	  in	  other	  exons	  of	  the	  G6PD	  mRNA	  (Fig.	  2A).	  	  While	  it	  only	  contains	  one	  of	  the	  introns	  surrounding	  exon	  12,	  the	  splicing	  and	  expression	  of	  the	  Exon	  12(+)	  reporter	  was	  regulated	  by	  insulin	  and	  fatty	  acids	  in	  an	  identical	  fashion	  to	  the	  endogenous	  gene	  following	  transfection	  into	  primary	  rat	  hepatocytes	  [3,	  23].	  	  Knockdown	  of	  hnRNP	  K	  with	  siRNA	  resulted	  in	  a	  69	  ±	  1%	  depletion	  of	  hnRNP	  K	  protein	  (Fig.	  2B).	  	  The	  depletion	  of	  hnRNP	  K	  was	  accompanied	  by	  a	  7-­‐fold	  or	  more	  increase	  in	  the	  amount	  of	  RNA	  produced	  by	  the	  Exon	  12(+)	  reporter	  (Fig.	  2C).	  	  This	  measurement	  does	  not	  discriminate	  between	  spliced	  and	  unspliced	  RNA	  and,	  thus	  this	  increase	  reflects	  primarily	  RNA	  that	  has	  been	  spliced,	  as	  the	  unspliced	  RNA	  is	  ultimately	  degraded.	  	  The	  overall	  increase	  in	  the	  accumulation	  of	  the	  reporter	  mRNA	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correlated	  with	  a	  significant	  increase	  in	  the	  amount	  of	  splicing	  of	  mRNA	  from	  the	  Exon	  12(+)	  reporter,	  indicating	  that	  RNA	  splicing	  was	  no	  longer	  being	  silenced	  (Fig	  2D).	  	  The	  increase	  in	  reporter	  RNA	  accumulation	  over	  and	  above	  what	  can	  be	  attributed	  to	  a	  change	  in	  splicing	  ratio	  may	  reflect	  that	  the	  less	  efficiently	  spliced	  RNA	  was	  being	  degraded	  in	  the	  cell	  without	  hnRNP	  K	  knockdown.	  	  HepG2	  cells	  that	  stably	  express	  the	  Exon	  12(-­‐)	  reporter	  were	  used	  as	  a	  negative	  control	  to	  show	  that	  the	  regulatory	  element	  in	  exon	  12	  is	  required	  for	  this	  regulation.	  	  As	  expected,	  the	  depletion	  of	  hnRNP	  K	  did	  not	  alter	  the	  accumulation	  of	  mRNA	  expressed	  from	  the	  Exon	  12(-­‐)	  reporter	  (Fig	  2E).	  	  SiRNA	  against	  hnRNP	  L	  caused	  a	  55	  ±	  6%	  depletion	  of	  hnRNP	  L	  but	  no	  change	  in	  the	  expression	  or	  splicing	  of	  the	  reporter	  RNA	  (Fig.	  2	  F-­‐H).	  	  Depletion	  of	  hnRNP	  L	  to	  amounts	  greater	  than	  this	  compromised	  cellular	  viability.	  	  The	  absence	  of	  a	  change	  in	  hnRNP	  L	  amount	  by	  nutritional	  status	  and	  the	  lack	  of	  an	  effect	  of	  hnRNP	  L	  depletion	  on	  G6PD	  splicing	  suggest	  that	  hnRNP	  L	  per	  se	  is	  not	  a	  required	  splicing	  regulator	  albeit	  it	  may	  play	  a	  regulatory	  role	  in	  combination	  of	  that	  provided	  by	  hnRNP	  K.	  	  These	  data	  support	  a	  hypothesis	  whereby	  hnRNP	  K	  inhibits	  splicing	  of	  G6PD	  mRNA	  and	  that	  the	  exon	  12	  regulatory	  element	  is	  involved	  in	  this	  response.	  
	  
3.3.	  	  Overexpression	  of	  hnRNP	  K	  decreases	  the	  splicing	  of	  G6PD	  mRNA	  
	   A	  gain-­‐of–function	  approach	  was	  used	  to	  test	  if	  hnRNP	  K	  inhibits	  splicing	  of	  G6PD	  mRNA	  in	  cells.	  Overexpression	  of	  hnRNP	  K	  was	  performed	  in	  the	  HepG2	  cells	  that	  stably	  express	  the	  G6PD	  reporters,	  Exon	  12(+)	  and	  Exon	  12(-­‐)	  (Fig.	  2A).	  Transfection	  of	  HepG2	  cells	  with	  a	  vector	  that	  results	  in	  expression	  of	  FLAG-­‐hnRNP	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K	  caused	  a	  53	  ±	  4%	  increase	  in	  hnRNP	  K	  protein	  over	  endogenous	  levels	  (Fig.	  3A).	  	  The	  increase	  in	  hnRNP	  K	  protein	  levels	  caused	  a	  60%	  decrease	  in	  the	  expression	  of	  mRNA	  from	  the	  Exon	  12(+)	  reporter	  as	  compared	  to	  control	  cells	  that	  were	  transfected	  with	  a	  vector	  expressing	  an	  unrelated	  protein,	  RFP	  (Fig.	  3B).	  	  To	  test	  for	  changes	  in	  splicing	  that	  could	  explain	  the	  decrease	  in	  expression	  of	  mRNA	  from	  the	  Exon	  12(+)	  reporter,	  primers	  were	  designed	  that	  would	  amplify	  exon	  12,	  intron	  12,	  and	  exon	  13	  (Fig.	  2A,	  black	  arrows).	  Amplification	  of	  the	  mRNA	  by	  RT-­‐PCR	  with	  these	  primers	  results	  in	  2	  products	  representing	  pre-­‐mRNA	  and	  spliced	  mRNA.	  After	  ectopic	  expression	  of	  hnRNP	  K,	  the	  extent	  of	  splicing	  of	  mRNA	  from	  the	  Exon	  12(+)	  reporter	  decreased	  80%	  when	  compared	  to	  control	  cells	  transfected	  with	  the	  vector	  expressing	  RFP	  (Fig.	  3C).	  	  Overexpression	  of	  hnRNP	  K	  in	  HepG2	  cells	  that	  express	  the	  Exon	  12(-­‐)	  reporter	  did	  not	  alter	  the	  expression	  of	  Exon	  12(-­‐)	  reporter	  mRNA	  (Fig.	  3D).	  	  Thus,	  even	  small	  increases	  in	  hnRNP	  K	  can	  inhibit	  splicing	  and	  the	  regulatory	  element	  within	  exon	  12	  is	  involved	  in	  the	  inhibition	  of	  splicing	  by	  hnRNP	  K.	  	  	  
	  
	   We	  next	  asked	  if	  overexpression	  of	  hnRNP	  K	  could	  decrease	  splicing	  of	  the	  endogenous	  G6PD	  gene.	  	  A	  clonal	  derivative	  of	  HepG2	  cells	  was	  developed	  that	  ectopically	  expresses	  hnRNP	  K	  under	  the	  control	  of	  a	  doxycycline	  inducible	  promoter.	  	  Incubation	  of	  the	  HepG2	  cells	  with	  doxycycline	  caused	  a	  40	  ±	  4%	  increase	  in	  the	  expression	  of	  hnRNP	  K	  (Fig.	  3E).	  	  Splicing	  of	  the	  endogenous	  mRNA	  could	  not	  be	  measured	  in	  total	  RNA	  isolates.	  	  Thus,	  chromatin	  associated	  RNA	  was	  isolated	  to	  enrich	  the	  samples	  in	  newly	  transcribed	  RNA.	  	  RT-­‐PCR	  and	  primers	  that	  
 79 
resulted	  in	  amplification	  across	  the	  exon-­‐intron	  boundaries	  surrounding	  exon	  12	  was	  used	  to	  measure	  the	  amount	  of	  endogenous	  G6PD	  pre-­‐mRNA.	  Following	  the	  induction	  of	  hnRNP	  K	  expression,	  G6PD	  mRNA	  retaining	  intron	  11	  and	  intron	  12	  increased	  by	  2-­‐fold	  or	  more	  compared	  to	  the	  clonal	  HepG2	  cells	  without	  doxycycline	  treatment	  or	  wild	  type	  HepG2	  cells	  treated	  with	  doxycycline	  (Fig.	  3F).	  	  The	  presence	  of	  these	  retained	  introns	  indicates	  a	  decrease	  in	  splicing	  efficiency.	  	  	  
	  
	   A	  final	  possibility	  is	  that	  hnRNP	  K	  action	  involves	  stabilization	  of	  the	  mRNA	  and	  this	  could	  confound	  the	  interpretation	  of	  splicing	  data.	  	  To	  test	  for	  mRNA	  stabilization	  apart	  from	  splicing,	  the	  HepG2	  cells	  were	  induced	  to	  express	  hnRNP	  K	  by	  doxycycline	  treatment.	  	  The	  cells	  were	  transfected	  with	  an	  RNA	  reporter	  that	  contained	  the	  G6PD	  cDNA	  as	  well	  as	  the	  G6PD	  3’-­‐UTR	  through	  the	  end	  of	  the	  gene.	  	  As	  stability	  elements	  can	  be	  within	  3’-­‐UTR,	  this	  plasmid	  would	  contain	  any	  such	  potential	  elements;	  however,	  the	  plasmid	  does	  not	  have	  introns	  from	  the	  G6PD	  gene	  and	  thus	  would	  not	  undergo	  exon	  12-­‐directed	  splicing.	  	  Following	  doxycycline	  treatment,	  FLAG-­‐hnRNP	  K	  expression	  was	  increased	  136	  ±	  4	  -­‐	  fold	  (n=5;	  blot	  not	  shown),	  but	  expression	  of	  mRNA	  from	  the	  cDNA	  reporter	  was	  not	  changed	  (Fig.	  3G).	  	  Thus,	  hnRNP	  K	  does	  not	  regulate	  stability	  of	  mRNA	  containing	  exon	  12.	  	  Together,	  these	  data	  demonstrate	  that	  hnRNP	  K	  is	  involved	  in	  the	  inhibition	  of	  splicing	  of	  G6PD	  mRNA.	  
	  
3.4.	  	  HnRNP	  K	  binds	  to	  the	  exon	  12	  regulatory	  element	  in	  cells	  
 80 
	   Our	  previously	  reported	  RNA	  affinity	  assays	  demonstrated	  that	  hnRNP	  K	  can	  bind	  to	  the	  splicing	  regulatory	  element	  in	  vitro	  [25].	  	  To	  determine	  if	  hnRNP	  K	  binds	  to	  the	  regulatory	  element	  in	  intact	  cells,	  we	  subjected	  the	  cells	  to	  chemical	  crosslinking	  and	  immunoprecipitated	  hnRNP	  K.	  	  RNA	  crosslinked	  to	  hnRNP	  K	  was	  detected	  by	  RT-­‐qPCR	  using	  primers	  that	  amplify	  exon	  12	  RNA	  produced	  by	  the	  Exon	  12(+)	  reporter.	  	  Because	  the	  reporter	  contains	  mouse	  sequences,	  reporter	  RNA	  can	  be	  amplified	  without	  interference	  of	  the	  endogenous	  gene.	  	  In	  HepG2	  cells	  expressing	  the	  Exon	  12(+)	  reporter,	  hnRNP	  K	  binding	  to	  the	  regulatory	  element	  was	  enriched	  14-­‐fold	  or	  more	  as	  compared	  to	  the	  IgG	  control	  (Fig.	  4A).	  	  This	  result	  was	  not	  due	  to	  incompletely	  fragmented	  RNA,	  as	  primers	  to	  the	  β-­‐galactosidase	  portion	  of	  the	  mRNA	  did	  not	  amplify	  RNA	  in	  the	  immunoprecipitate.	  	  Thus	  hnRNP	  K	  is	  binding	  to	  the	  exon	  12	  regulatory	  element	  in	  intact	  cells.	  
	  
3.5.	  	  Starvation	  enhances	  the	  binding	  of	  hnRNP	  K	  to	  the	  splicing	  regulatory	  element	  in	  
vivo	  
	   In	  intact	  animals,	  starvation	  inhibits	  G6PD	  splicing	  and	  causes	  retention	  of	  introns	  surrounding	  exon	  12	  [23].	  To	  test	  if	  hnRNP	  K	  interaction	  with	  the	  regulatory	  element	  is	  regulated	  by	  nutritional	  status	  in	  intact	  liver,	  we	  performed	  RIP	  using	  mice	  that	  had	  been	  starved	  or	  starved	  and	  then	  refed	  a	  high-­‐carbohydrate	  diet.	  	  The	  livers	  were	  subjected	  to	  chemical	  crosslinking	  and	  the	  amount	  of	  hnRNP	  K	  bound	  to	  the	  exon	  12	  regulatory	  element	  was	  measured	  by	  RT-­‐qPCR.	  	  Exon	  12	  RNA	  was	  enriched	  in	  the	  hnRNP	  K	  immunoprecipitates	  by	  23-­‐fold	  or	  more	  compared	  to	  the	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IgG	  control	  (Fig.	  4B).	  	  Furthermore,	  starvation	  caused	  a	  12.5-­‐fold	  increase	  in	  hnRNP	  K	  bound	  to	  regulatory	  element	  compared	  to	  refed	  mice.	  	  Binding	  of	  hnRNP	  K	  in	  the	  livers	  of	  refed	  mice	  was	  barely	  detectable	  and	  was	  similar	  to	  the	  amounts	  detected	  following	  immunoprecipitation	  with	  IgG	  (Fig.	  4B).	  	  To	  test	  if	  the	  starvation-­‐induced	  increase	  in	  hnRNP	  K	  binding	  was	  specific	  to	  G6PD,	  RNA	  corresponding	  to	  glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	  (GAPDH)	  was	  also	  measured.	  	  Expression	  of	  GAPDH	  is	  not	  regulated	  by	  starvation	  and	  refeeding	  [22,	  32].	  	  Starvation	  did	  not	  significantly	  alter	  the	  presence	  of	  GAPDH	  mRNA	  in	  hnRNP	  K	  immunoprecipitates	  and	  enrichment	  relatively	  to	  IgG	  was	  low	  in	  both	  dietary	  conditions	  (Fig.	  4C).	  	  Our	  previous	  data	  has	  clearly	  demonstrated	  that	  decreased	  splicing	  of	  exon	  12	  is	  the	  primary	  mechanism	  by	  which	  starvation	  decreases	  G6PD	  mRNA	  abundance	  [3,	  22,	  23].	  	  In	  this	  experiment,	  the	  increase	  in	  hnRNP	  K	  binding	  correlated	  with	  a	  60%	  decrease	  in	  the	  abundance	  of	  G6PD	  mRNA	  in	  the	  same	  livers	  (Fig.	  4D).	  In	  summary,	  hnRNP	  K	  inhibits	  the	  splicing	  of	  G6PD	  mRNA,	  it	  binds	  to	  the	  regulatory	  element	  in	  exon	  12	  of	  this	  RNA,	  and	  this	  binding	  is	  enhanced	  by	  starvation.	  	  Together	  these	  data	  are	  consistent	  with	  the	  hypothesis	  that	  hnRNP	  K	  is	  a	  starvation-­‐induced	  splicing	  silencer.	  
	  
3.6.	  	  HnRNP	  K	  binds	  to	  C-­‐rich	  motifs	  within	  exon	  12	  of	  G6PD	  mRNA	  
	   We	  have	  previously	  demonstrated	  the	  SRSF3	  also	  binds	  to	  exon	  12	  of	  the	  G6PD	  mRNA	  and	  in	  contrast	  to	  hnRNP	  K,	  its	  binding	  is	  decreased	  by	  starvation	  and	  increased	  by	  refeeding	  [24].	  HnRNP	  K	  is	  known	  to	  form	  complexes	  with	  other	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proteins	  and	  therefore	  we	  asked	  if	  hnRNP	  K	  per	  se	  could	  bind	  to	  G6PD	  RNA	  and	  if	  its	  binding	  site	  co-­‐localized	  with	  the	  sequences	  required	  for	  SRSF3	  binding.	  	  The	  splicing	  regulatory	  element	  in	  exon	  12	  of	  the	  G6PD	  mRNA	  encompasses	  nt	  43-­‐72	  of	  the	  93	  nt	  exon	  and	  contains	  two	  C-­‐rich	  sequences,	  which	  are	  known	  to	  be	  hnRNP	  K	  binding	  motifs	  [19,	  33].	  	  A	  third	  motif	  is	  located	  downstream	  of	  the	  splicing	  regulatory	  element;	  thus	  the	  entire	  region	  was	  used	  in	  RNA	  EMSAs	  to	  evaluate	  binding	  of	  hnRNP	  K	  to	  exon	  12	  (Fig.	  5A).	  	  Incubation	  of	  a	  HEX-­‐labelled	  probe	  representing	  nt	  50	  to	  83	  and	  recombinant	  hnRNP	  K	  protein	  resulted	  in	  two	  shifted	  bands	  (Fig.	  5B,	  lane	  1).	  	  The	  reason	  for	  2	  bands	  was	  not	  clear,	  thus	  a	  supershift	  was	  performed	  to	  determine	  which	  band	  represents	  the	  hnRNP	  K	  and	  RNA	  complex.	  	  The	  addition	  of	  hnRNP	  K	  specific	  antibody	  resulted	  in	  a	  supershift	  of	  both	  bands	  suggesting	  that	  they	  are	  protein:RNA	  complexes	  although	  this	  does	  not	  rigorously	  eliminate	  probe	  secondary	  structure	  or	  a	  peptide	  from	  hnRNP	  K	  degradation	  as	  a	  cause	  of	  the	  lower	  band	  (Fig.	  5B,	  lane	  2).	  	  Increasing	  concentrations	  of	  the	  WT	  specific	  competitor	  (Fig.	  5A)	  were	  able	  to	  compete	  for	  binding	  of	  hnRNP	  K	  (Fig.	  5C).	  	  In	  contrast,	  mutation	  of	  all	  three	  C-­‐rich	  motifs	  within	  this	  RNA	  oligonucleotide	  abrogated	  binding	  to	  hnRNP	  K	  (92%	  decrease	  in	  the	  shifted	  band	  with	  the	  WT	  competitor	  versus	  a	  12%	  decrease	  for	  the	  triple	  mutant	  at	  100X;	  Fig.	  5C).	  	  To	  further	  localize	  the	  sequences	  involved	  in	  binding,	  competitions	  were	  performed	  with	  oligonucleotides	  containing	  mutations	  of	  the	  C-­‐rich	  motif	  at	  nt	  65-­‐68	  or	  the	  C-­‐rich	  motif	  at	  nt	  71-­‐73.	  	  Mutants	  missing	  only	  a	  single	  C-­‐rich	  motif	  were	  able	  to	  reduce	  binding	  of	  hnRNP	  K	  to	  the	  HEX-­‐labelled	  probe	  by	  52%	  and	  40%	  at	  100X,	  respectively	  (Fig.	  5D);	  however,	  when	  both	  of	  these	  C-­‐rich	  motifs	  were	  mutated,	  the	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oligonucleotide	  failed	  to	  compete	  for	  hnRNP	  K	  binding	  (Fig.	  5E).	  	  Thus	  the	  C-­‐rich	  motif	  downstream	  of	  the	  regulatory	  element	  was	  unable	  to	  compensate	  for	  the	  loss	  of	  the	  C-­‐rich	  motifs	  at	  nt	  65-­‐68	  and	  71-­‐73,	  which	  is	  consistent	  with	  our	  functional	  data	  that	  defined	  the	  silencing	  element	  to	  the	  nt	  43-­‐72	  region	  of	  exon	  12	  [3].	  	  These	  results	  indicate	  that	  hnRNP	  K	  binds	  directly	  to	  the	  RNA	  and	  further	  the	  region	  between	  nt	  65-­‐73	  co-­‐localizes	  with	  the	  sequence	  to	  which	  SRSF3	  binds.	  
	  
3.7.	  	  HnRNP	  K	  and	  SRSF3	  compete	  for	  binding	  to	  the	  exon	  12	  regulatory	  element	  
	   SRSF3	  binds	  to	  nt	  62-­‐72	  of	  exon	  12,	  which	  contains	  the	  first	  C-­‐rich	  motif	  that	  was	  necessary	  for	  maximal	  hnRNP	  K	  binding	  [24].	  RNA	  EMSAs	  were	  used	  to	  test	  for	  competition	  between	  hnRNP	  K	  and	  SRSF3	  for	  binding	  to	  the	  regulatory	  element.	  	  Addition	  of	  SRSF3	  to	  the	  binding	  reaction	  failed	  to	  decrease	  the	  binding	  of	  K	  to	  the	  HEX-­‐labelled	  probe	  (Fig.	  6,	  lanes	  1	  and	  2).	  	  In	  contrast,	  even	  small	  amounts	  of	  hnRNP	  K	  effectively	  competed	  with	  SRSF3	  for	  binding	  (Fig.	  6,	  lanes	  3,4	  and	  5).	  	  This	  is	  despite	  the	  fact	  that	  SRSF3	  was	  present	  in	  28	  and	  7-­‐fold	  molar	  excess	  over	  hnRNP	  K.	  	  Thus,	  hnRNP	  K	  and	  SRSF3	  binding	  appears	  to	  be	  mutually	  exclusive	  and	  the	  ability	  of	  hnRNP	  K	  to	  block	  SRSF3	  binding	  suggests	  a	  dominant	  effect	  of	  hnRNP	  K	  on	  regulating	  splicing	  of	  G6PD	  pre-­‐mRNA.	  
	  
4.	  	  DISCUSSION	  
	   The	  starved	  and	  fed	  states	  are	  regulatory	  challenges	  faced	  by	  all	  vertebrates.	  	  The	  need	  to	  switch	  between	  fuel	  storage	  and	  use	  occurs	  on	  a	  daily	  basis	  as	  the	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organism	  responds	  to	  limited	  periods	  of	  food	  consumption	  such	  as	  between	  meals	  or	  prolonged	  starvation	  during	  illness	  or	  lack	  of	  food	  availability.	  	  We	  have	  developed	  a	  body	  of	  evidence	  that	  demonstrates	  that	  the	  RNA	  splicing	  machinery	  is	  an	  intracellular	  target	  for	  regulation	  during	  starvation.	  	  The	  G6PD	  gene	  has	  provided	  a	  useful	  tool	  for	  these	  studies	  because	  starvation	  and	  refeeding	  result	  in	  large	  changes	  in	  the	  accumulation	  of	  G6PD	  mRNA	  and	  do	  so	  solely	  by	  regulating	  the	  rate	  of	  splicing	  of	  the	  G6PD	  transcript	  [34].	  	  During	  starvation,	  decreased	  splicing	  of	  exon	  12	  results	  in	  the	  retention	  of	  the	  surrounding	  introns	  and	  degradation	  of	  the	  transcript.	  A	  cis-­‐acting	  element	  in	  exon	  12	  is	  required	  for	  regulated	  splicing	  of	  G6PD	  pre-­‐mRNA	  [3].	  	  In	  this	  report,	  we	  demonstrate	  that	  hnRNP	  K	  is	  a	  starvation-­‐induced	  splicing	  factor	  that	  binds	  to	  this	  cis-­‐acting	  element	  and	  inhibits	  splicing	  of	  the	  G6PD	  pre-­‐mRNA.	  	  
	   HnRNP	  K	  binds	  to	  the	  regulatory	  element	  via	  2	  C-­‐rich	  motifs	  (Fig.	  5).	  	  These	  C-­‐rich	  binding	  sites	  are	  similar	  to	  other	  known	  binding	  sites	  that	  have	  been	  identified	  for	  hnRNP	  K	  by	  SELEX.	  Of	  note,	  a	  third	  C-­‐rich	  motif	  just	  downstream	  of	  the	  nt	  42-­‐73	  regulatory	  element	  did	  not	  bind	  hnRNP	  K	  effectively.	  	  Thus,	  hnRNP	  K	  binding	  does	  exhibit	  some	  selectivity.	  In	  contrast	  to	  hnRNP	  K,	  hnRNPs	  L	  and	  A2/B1	  also	  bound	  to	  the	  regulatory	  element	  in	  RNA	  affinity	  assays	  [25]	  but	  failed	  to	  show	  regulation	  of	  G6PD	  expression	  or	  selectivity	  in	  further	  analysis.	  An	  interaction	  between	  these	  proteins	  and	  hnRNP	  K	  has	  been	  demonstrated	  and	  thus	  their	  appearance	  in	  the	  RNA	  affinity	  assay	  may	  only	  occur	  in	  vitro	  [35,	  36].	  	  Alternatively,	  they	  may	  play	  a	  role	  enhancing	  the	  action	  of	  hnRNP	  K	  or	  in	  combination	  with	  other	  splicing	  regulators.	  	  Nonetheless,	  a	  sharp	  change	  in	  splicing	  regulation	  was	  not	  seen	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with	  hnRNP	  L	  deletion	  alone	  to	  the	  extent	  observed	  with	  hnRNP	  K.	  	  Highlighting	  the	  role	  for	  hnRNP	  K	  in	  G6PD	  expression,	  an	  interaction	  between	  hnRNP	  K	  and	  the	  RNA	  was	  observed	  in	  both	  intact	  cells	  and	  liver	  tissue	  (Fig.	  4).	  The	  binding	  of	  hnRNP	  K	  to	  the	  regulatory	  element	  in	  exon	  12	  is	  enhanced	  following	  starvation,	  and	  this	  increase	  in	  binding	  coincides	  with	  decreased	  accumulation	  of	  G6PD	  mRNA.	  	  In	  addition	  to	  the	  direct	  interaction	  between	  hnRNP	  K	  and	  the	  RNA,	  loss	  of	  function	  and	  gain	  of	  function	  experiments	  further	  highlight	  the	  role	  of	  hnRNP	  K	  in	  silencing	  splicing	  of	  G6PD	  pre-­‐mRNA.	  While,	  hnRNP	  K	  was	  relatively	  abundant	  in	  the	  refed	  livers,	  our	  data	  with	  overexpression	  of	  hnRNP	  K	  in	  HepG2	  cells	  demonstrate	  that	  even	  small	  increases	  in	  the	  amount	  of	  this	  protein	  in	  the	  cells,	  can	  cause	  changes	  in	  the	  splicing	  of	  G6PD	  mRNA	  (Fig.	  3).	  Our	  results	  demonstrate	  that	  hnRNP	  K	  plays	  an	  important	  role	  in	  regulating	  splicing	  in	  response	  to	  nutritional	  stimuli.	  	  	  
	   The	  fact	  that	  expression	  of	  hnRNP	  K	  protein	  is	  increased	  following	  periods	  of	  starvation	  provides	  additional	  evidence	  for	  a	  regulatory	  role	  linking	  splicing	  changes	  to	  dietary	  cues.	  To	  our	  knowledge,	  this	  is	  the	  first	  evidence	  that	  hnRNP	  K	  expression	  is	  regulated	  by	  dietary	  changes	  in	  the	  liver.	  	  Nutritional	  status	  may	  regulate	  hnRNP	  K	  via	  the	  hormones,	  insulin	  and	  glucagon,	  which	  change	  in	  abundance	  between	  the	  starved	  and	  refed	  states.	  	  In	  this	  regard,	  diabetes	  is	  associated	  with	  an	  increase	  in	  hnRNP	  K	  expression	  in	  proximal	  renal	  tubular	  cells	  and	  insulin	  reverses	  this	  effect	  [37].	  	  The	  regulation	  of	  hnRNP	  K	  in	  liver	  may	  involve	  a	  similar	  effect	  as	  starvation	  and	  diabetes	  both	  involve	  decreased	  insulin	  action.	  	  Because	  hnRNP	  K	  has	  other	  cellular	  targets	  such	  as	  inhibition	  of	  the	  production	  of	  the	  pro-­‐apoptotic	  Bcl-­‐xs	  splice	  isoform	  [38],	  as	  well	  as,	  enhancing	  the	  transcriptional	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activity	  of	  p53	  [18,	  39,	  40],	  regulation	  of	  its	  activity	  by	  starvation	  may	  have	  multiple	  additional	  targets.	  
	   The	  changes	  observed	  in	  the	  expression	  of	  hnRNP	  K	  protein	  may	  only	  be	  partially	  responsible	  for	  the	  increase	  in	  hnRNP	  K	  binding	  to	  the	  G6PD	  regulatory	  element	  and	  the	  decrease	  in	  accumulation	  G6PD	  mRNA.	  	  HnRNP	  K	  is	  subject	  to	  various	  posttranslational	  modifications,	  including	  phosphorylation,	  sumoylation	  and	  methylation,	  which	  could	  play	  a	  role	  in	  regulating	  it	  actions	  [17-­‐19,	  21,	  40-­‐42].	  Preliminary	  studies	  in	  primary	  rat	  hepatocytes	  did	  not	  show	  a	  change	  in	  either	  serine	  or	  tyrosine	  phosphorylation	  during	  insulin	  treatment	  (Cyphert	  and	  Salati,	  unpublished).	  We	  also	  tested	  for	  palmitoylation	  of	  hnRNP	  K,	  but	  none	  was	  observed	  (Cyphert	  and	  Salati,	  unpublished).	  	  An	  additional	  possibility	  is	  the	  recruitment	  of	  other	  splicing	  silencers.	  	  HnRNP	  L	  also	  bound	  to	  the	  regulatory	  element.	  	  While	  its	  absence	  from	  the	  cells	  did	  not	  enhance	  G6PD	  expression,	  its	  role	  may	  be	  complimented	  by	  other	  splicing	  regulatory	  factors,	  such	  as	  the	  hnRNP	  L-­‐like	  protein	  [27].	  	  Establishing	  these	  mechanisms	  are	  active	  areas	  for	  future	  research.	  
	   Strong	  evidence	  exists	  for	  a	  model	  whereby	  regulated	  splicing	  involves	  a	  competition	  between	  hnRNP	  K	  and	  SRSF3	  for	  binding	  to	  the	  exon	  12	  regulatory	  element.	  Both	  proteins	  bind	  between	  nt	  63	  and	  73	  and	  the	  binding	  is	  regulated	  by	  starvation	  and	  refeeding	  (Fig.	  5	  and	  ref.	  [24].	  	  In	  contrast	  with	  hnRNP	  K,	  SRSF3	  binding	  in	  vivo	  is	  enhanced	  by	  refeeding	  and	  inhibited	  by	  starvation	  [24].	  The	  binding	  of	  SRSF3	  to	  the	  regulatory	  element	  in	  intact	  liver	  coincides	  with	  an	  increase	  in	  the	  splicing	  of	  the	  G6PD	  mRNA	  and	  the	  regulating	  splicing	  is	  dependent	  on	  the	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presence	  of	  exon	  12	  [3,	  23].	  	  These	  results	  support	  the	  concept	  of	  mutually	  exclusive	  binding	  of	  these	  regulatory	  factors	  as	  a	  mechanism	  to	  control	  splicing	  of	  the	  exon.	  	  This	  hypothesis	  is	  also	  consistent	  with	  the	  observed	  competition	  between	  SRSF3	  and	  splicing	  silencers	  in	  the	  regulation	  of	  the	  alternative	  splicing	  of	  the	  insulin	  receptor	  [43].	  	  With	  respect	  to	  G6PD,	  hnRNP	  K	  appears	  to	  play	  a	  dominant	  role	  inhibiting	  splicing.	  	  HnRNP	  K	  competes	  against	  even	  molar	  excesses	  of	  SRSF3	  for	  binding	  to	  the	  regulatory	  element	  (Fig.	  6).	  	  Effective	  competition	  by	  SRSF3	  may	  require	  phosphorylation	  in	  response	  to	  stimulatory	  signals.	  	  G6PD	  expression	  in	  liver	  is	  very	  low	  until	  stimulated	  to	  increase	  by	  insulin	  or	  a	  high	  carbohydrate	  diet	  [22,	  44].	  	  Competition	  between	  hnRNP	  K	  and	  SRSF3	  may	  regulate	  G6PD	  expression	  beyond	  the	  requirements	  for	  energy	  homeostasis.	  	  In	  this	  regard,	  G6PD	  expression	  is	  also	  elevated	  in	  liver	  tumors	  as	  compared	  to	  normal	  liver	  tissue	  [45].	  	  HnRNP	  K	  amount	  is	  decreased	  in	  tumors	  as	  compared	  to	  normal	  liver	  [45];	  in	  contrast,	  SRSF3	  is	  increased	  in	  human	  tumors	  and	  rat	  hepatoma	  cells	  and	  it	  abundance	  is	  very	  low	  in	  normal	  liver	  and	  in	  rat	  hepatocytes	  (Jia,	  2010	  and	  Cyphert	  and	  Salati,	  unpublished).	  	  	  
	   In	  conclusion,	  hnRNP	  K	  joins	  SRSF3	  as	  a	  nutrient	  regulated	  splicing	  factor.	  	  In	  addition,	  it	  establishes	  a	  role	  for	  hnRNP	  K	  for	  regulation	  of	  splicing	  via	  intron	  retention.	  	  Nutrient	  regulated	  splicing	  is	  likely	  occurring	  with	  other	  metabolic	  genes	  and	  the	  understanding	  of	  how	  these	  inhibitory	  and	  enhancing	  factors	  interact	  is	  essential	  for	  understanding	  how	  nutrients	  regulate	  metabolic	  processes.	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FIGURES	  LEGENDS	  
Figure	  1.	  Starvation	  causes	  an	  increase	  in	  the	  amount	  of	  hnRNP	  K	  protein	  in	  mice	  livers.	  Mice	  were	  either	  starved	  for	  18	  h	  or	  starved	  for	  18	  h	  and	  then	  refed	  a	  high	  carbohydrate	  diet	  for	  12	  h	  and	  protein	  extracts	  were	  made	  from	  the	  mouse	  livers	  as	  described	  in	  the	  materials	  and	  methods.	  (A)	  A	  western	  blot	  shows	  the	  amount	  of	  hnRNP	  K	  in	  the	  livers	  of	  mice.	  Each	  lane	  represents	  an	  individual	  mouse	  liver.	  Quantification	  of	  the	  changes	  in	  the	  amount	  of	  hnRNP	  K	  protein	  is	  shown.	  The	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amount	  of	  hnRNP	  K	  protein	  was	  normalized	  to	  the	  amount	  of	  β-­‐tubulin.	  The	  data	  are	  the	  mean	  ±	  SE	  of	  n=3	  mice	  per	  group.	  (B)	  A	  western	  blot	  shows	  the	  amounts	  of	  hnRNP	  L	  and	  A2/B1	  in	  the	  livers	  of	  mice.	  	  Each	  lane	  represents	  an	  individual	  mouse	  liver.	  These	  antibodies	  detect	  2	  bands	  for	  each	  of	  these	  proteins.	  	  The	  reason	  for	  the	  doublet	  is	  not	  apparent.	  	  Quantification	  of	  the	  changes	  in	  the	  amount	  of	  hnRNP	  L	  and	  A2/B1	  protein	  is	  shown.	  The	  amount	  of	  hnRNP	  L	  and	  A2/B1	  protein	  was	  normalized	  to	  the	  amount	  of	  β-­‐tubulin.	  The	  data	  are	  the	  mean	  ±	  SE	  of	  n=3	  mice	  per	  group.	  	  (C)	  Nuclear	  extracts	  were	  prepared	  from	  mice	  that	  were	  starved	  or	  starved	  then	  refed	  and	  immunoblotted	  for	  hnRNP	  A2/B1.	  Each	  lane	  represents	  an	  individual	  mouse	  liver.	  	  Quantification	  of	  the	  changes	  in	  the	  amount	  of	  hnRNP	  A2/B1	  protein	  was	  performed	  on	  the	  Typhoon	  imager	  and	  is	  shown.	  The	  data	  are	  the	  mean	  ±	  SE	  of	  n=4	  mice	  per	  group.	  	  S,	  starved;	  R,	  refed.	  	  The	  “*”	  symbol	  indicated	  a	  significant	  difference	  (p<0.05).	  
	  
Figure	  2.	  	  Depletion	  of	  hnRNP	  K	  by	  siRNA	  causes	  an	  increase	  in	  the	  splicing	  of	  G6PD	  mRNA.	  HepG2	  cells	  stably	  expressing	  the	  G6PD	  reporter	  shown	  in	  (A)	  were	  transfected	  with	  100nM	  siRNA	  against	  hnRNP	  K,	  hnRNP	  L,	  or	  a	  non-­‐targeting	  (NT)	  control.	  After	  48	  hours,	  RNA	  and	  protein	  were	  isolated.	  	  The	  Exon	  12(+)	  reporter	  contains	  mouse	  genomic	  DNA	  from	  exon	  12	  (nt	  37-­‐93),	  intron	  12,	  and	  exon	  13	  including	  the	  entire	  3’-­‐untranslated	  region	  (3’-­‐UTR)	  of	  the	  G6PD	  gene	  ligated	  to	  β-­‐galactosidase	  (β-­‐gal)	  and	  transcription	  is	  driven	  by	  the	  CMV	  promoter.	  The	  open	  arrows	  indicate	  the	  location	  of	  the	  primers	  used	  to	  detect	  overall	  reporter	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expression.	  The	  closed	  arrows	  represent	  primers	  used	  to	  detect	  the	  splicing	  of	  the	  reporter.	  The	  Exon	  12(-­‐)	  vector	  also	  contains	  mouse	  genomic	  DNA	  ligated	  to	  β-­‐galactosidase	  but	  contains	  only	  the	  last	  8	  nt	  of	  exon	  12	  to	  preserve	  the	  5’splice	  site	  (5’SS)	  of	  intron	  12.	  (B)	  A	  representative	  immunoblot	  of	  hnRNP	  K	  depletion	  in	  HepG2	  cells	  is	  shown.	  (C)	  Expression	  of	  mRNA	  produced	  by	  the	  Exon	  12(+)	  reporter	  in	  HepG2	  cells	  that	  were	  transfected	  with	  the	  indicated	  siRNA	  was	  measured	  with	  the	  primers	  to	  the	  β-­‐galactosidase	  sequence	  (open	  arrows).	  The	  data	  are	  normalized	  to	  the	  amount	  of	  GAPDH	  mRNA.	  The	  data	  are	  the	  mean	  ±	  SE	  of	  n=6	  independent	  siRNA	  knockdowns.	  	  (D)	  Following	  knockdowns	  with	  the	  indicated	  siRNA,	  splicing	  of	  the	  reporter	  RNA	  was	  with	  the	  primers	  indicated	  by	  black	  arrows.	  The	  products	  of	  a	  representative	  RT-­‐PCR	  are	  shown.	  	  Samples	  were	  also	  amplified	  without	  prior	  treatment	  with	  reverse	  transcriptase	  (RT)	  to	  test	  for	  DNA	  contamination.	  	  The	  percentage	  of	  mRNA	  that	  was	  spliced	  is	  calculated	  as	  the	  intensity	  of	  the	  spliced	  band	  over	  the	  combined	  intensities	  of	  the	  bands	  for	  spliced	  and	  unspliced	  RNA.	  The	  data	  represent	  the	  mean	  ±	  SE	  of	  n=6	  independent	  siRNA	  transfections.	  (E)	  Expression	  of	  the	  Exon	  12(-­‐)	  reporter	  in	  HepG2	  cells	  that	  were	  transfected	  with	  the	  indicated	  siRNAs	  was	  measured	  by	  RT-­‐qPCR	  and	  primers	  to	  the	  β-­‐galactosidase	  portion	  of	  the	  reporter	  RNA.	  The	  amount	  of	  reporter	  mRNA	  is	  expressed	  relative	  to	  the	  amount	  of	  GAPDH	  mRNA.	  Each	  bar	  represents	  the	  mean	  ±	  SE	  n=3	  independent	  siRNA	  transfections.	  	  (F-­‐H)	  Knockdown	  of	  hnRNP	  L	  and	  measurement	  of	  Exon	  12(+)	  reporter	  expression	  and	  splicing	  were	  carried	  out	  as	  described	  for	  hnRNP	  L.	  	  Each	  bar	  represents	  the	  mean	  ±	  SE	  n=4	  independent	  siRNA	  transfections.	  	  The	  “*”	  symbol	  indicates	  a	  significant	  difference	  (p<0.05).	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Figure	  3.	  Ectopic	  expression	  of	  hnRNP	  K	  decreases	  the	  splicing	  of	  G6PD	  mRNA.	  HepG2	  cells	  that	  stably	  express	  either	  the	  Exon	  12(+)	  reporter	  or	  Exon	  12(-­‐)	  were	  transfected	  with	  a	  construct	  containing	  Myc-­‐FLAG-­‐tagged	  hnRNP	  K.	  After	  48	  hours,	  RNA	  and	  protein	  were	  isolated	  from	  the	  cells	  and	  the	  effects	  of	  ectopically	  expressing	  hnRNP	  K	  (Myc-­‐FLAG-­‐hnRNP	  K)	  or	  the	  control	  (RFP)	  on	  reporter	  splicing	  and	  expression	  were	  measured.	  (A)	  A	  representative	  immunoblot	  of	  the	  ectopic	  expression	  of	  Myc-­‐FLAG-­‐hnRNP	  K	  is	  shown.	  Ectopically	  expressed	  hnRNP	  K	  was	  detected	  with	  FLAG-­‐specific	  antibody.	  An	  hnRNP	  K	  specific	  antibody	  was	  used	  to	  detect	  both	  the	  endogenous	  (lower	  band)	  and	  ectopically	  expressed	  (upper	  band)	  hnRNP	  K	  proteins.	  (B)	  Expression	  of	  the	  Exon	  12(+)	  reporter	  in	  HepG2	  cells	  that	  were	  transfected	  with	  the	  indicated	  vectors	  was	  measured	  by	  RT-­‐qPCR	  and	  primers	  to	  the	  β-­‐galactosidase	  portion	  of	  the	  RNA	  (see	  Fig.	  2A).	  The	  amount	  of	  reporter	  mRNA	  is	  expressed	  relative	  to	  the	  amount	  of	  GAPDH	  mRNA,	  which	  is	  not	  regulated	  by	  these	  treatments.	  Each	  bar	  is	  the	  mean	  ±	  SE	  of	  n=3	  independent	  transfections.	  	  (C)	  Splicing	  of	  the	  Exon	  12(+)	  reporter	  was	  measured	  by	  RT-­‐PCR	  and	  the	  primers	  indicated	  in	  Fig.	  2A	  followed	  by	  separation	  of	  the	  products	  on	  a	  2%	  agarose	  gel.	  	  A	  representative	  gel	  is	  shown.	  	  Samples	  were	  also	  amplified	  without	  prior	  treatment	  with	  reverse	  transcriptase	  (RT)	  to	  test	  for	  DNA	  contamination.	  	  The	  percentage	  of	  mRNA	  that	  was	  spliced	  is	  calculated	  as	  the	  intensity	  of	  the	  spliced	  band	  over	  the	  combined	  intensities	  of	  the	  bands	  for	  spliced	  and	  unspliced	  RNA.	  	  The	  data	  are	  the	  mean	  ±	  SE	  of	  n=3	  independent	  hnRNP	  K	  transfections.	  	  (D)	  Expression	  of	  the	  Exon	  12(-­‐)	  reporter	  in	  HepG2	  cells	  that	  were	  transfected	  with	  the	  indicated	  vectors	  was	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measured	  by	  RT-­‐qPCR	  and	  primers	  to	  the	  β-­‐galactosidase	  portion	  of	  the	  RNA.	  The	  amount	  of	  reporter	  mRNA	  is	  expressed	  relative	  to	  the	  amount	  of	  GAPDH	  mRNA.	  Each	  bar	  is	  the	  mean	  ±	  SE	  of	  n=3	  independent	  hnRNP	  K	  transfections.	  	  (E)	  HepG2	  cells	  that	  stably	  express	  doxycycline-­‐inducible	  FLAG-­‐hnRNP	  K	  were	  treated	  with	  doxycycline	  (Dox)	  to	  increase	  the	  amount	  of	  hnRNP	  K	  protein.	  	  The	  arrow	  indicates	  the	  FLAG-­‐tagged	  hnRNP	  K	  detected	  with	  the	  hnRNP	  K	  antibody.	  	  (F)	  	  The	  primers	  used	  for	  RT-­‐qPCR	  are	  indicated	  on	  the	  gene	  diagram.	  	  Chromatin-­‐associated	  RNA	  that	  represents	  newly	  transcribed	  RNA	  was	  isolated	  and	  the	  amount	  of	  endogenous	  G6PD	  mRNA	  was	  measured	  by	  RT-­‐qPCR.	  	  The	  data	  are	  expressed	  as	  the	  amount	  of	  mRNA	  containing	  intron	  11	  (graph	  on	  left)	  or	  intron	  12	  (graph	  on	  right)	  relative	  to	  the	  amount	  of	  cyclophilin	  mRNA.	  The	  data	  are	  the	  mean	  ±	  SE	  of	  n=3	  independent	  experiments.	  The	  “*”	  symbol	  indicates	  a	  significant	  difference	  (p<0.05).	  The	  increase	  in	  hnRNP	  K	  expression	  by	  doxycycline	  is	  shown.	  	  (G)	  	  Following	  induction	  of	  hnRNP	  K	  expression	  with	  doxycycline	  (Dox),	  the	  HepG2	  cells	  were	  transiently	  transfected	  with	  a	  reporter	  expressing	  the	  mouse	  G6PD	  cDNA	  as	  described	  in	  Materials	  and	  Methods.	  	  RNA	  was	  isolated	  24	  h	  later	  and	  mRNA	  produced	  by	  the	  reporter	  was	  measured	  by	  RT-­‐pPCR	  and	  primers	  specific	  for	  the	  mouse	  mRNA.	  	  The	  data	  are	  expressed	  relative	  to	  the	  amount	  of	  GAPDH	  mRNA	  and	  are	  the	  mean	  ±	  SE	  of	  n=5	  independent	  transfections.	  
	  
Figure	  4.	  HnRNP	  K	  binds	  to	  exon	  12	  of	  the	  G6PD	  mRNA	  and	  in	  mouse	  liver;	  the	  binding	  is	  enhanced	  by	  starvation.	  (A)	  HepG2	  cells	  expressing	  the	  Exon	  12(+)	  reporter	  were	  crosslinked	  with	  formaldehyde	  and	  hnRNP	  K	  was	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immunoprecipitated	  from	  the	  lysates.	  G6PD	  mRNA	  bound	  to	  hnRNP	  K	  was	  measured	  by	  RT-­‐qPCR	  and	  primers,	  which	  amplify	  the	  region	  of	  the	  reporter	  RNA	  from	  the	  end	  of	  β-­‐galactosidase	  to	  the	  end	  of	  exon	  12.	  Immunoprecipitation	  with	  IgG	  was	  used	  as	  a	  control	  for	  non-­‐specific	  binding.	  Immunoprecipitation	  with	  hnRNP	  K	  or	  IgG	  followed	  by	  RT-­‐qPCR	  of	  an	  upstream	  region	  of	  β-­‐galactosidase	  (open	  arrows	  Fig	  2A)	  was	  used	  as	  a	  control	  for	  non-­‐specific	  pull-­‐down	  of	  reporter	  RNA.	  The	  amount	  of	  RNA	  detected	  is	  expressed	  relative	  to	  input	  RNA	  in	  each	  sample.	  The	  abbreviation	  “ND”	  represents	  not	  detectable.	  (B)	  Mice	  were	  either	  starved	  for	  18	  h	  or	  starved	  for	  18	  h	  and	  then	  refed	  a	  high	  carbohydrate	  diet	  for	  12	  h.	  Following	  the	  formaldehyde	  crosslinking	  of	  the	  livers,	  RNA	  bound	  to	  hnRNP	  K	  was	  precipitated	  using	  an	  antibody	  against	  hnRNP	  K,	  or	  IgG	  as	  a	  control.	  Equal	  amounts	  of	  protein	  from	  the	  crosslinked	  lysates	  were	  added	  to	  each	  immunoprecipitation.	  G6PD	  mRNA	  immunoprecipitated	  with	  hnRNP	  K	  or	  IgG	  was	  detected	  with	  RT-­‐qPCR	  and	  primers	  nucleotides	  18-­‐89	  of	  exon	  12,	  which	  contains	  the	  regulatory	  element	  (nucleotides	  43	  to	  72).	  The	  amount	  of	  detected	  RNA	  is	  expressed	  relative	  to	  the	  input	  RNA	  in	  each	  sample.	  The	  “*”	  symbol	  indicates	  a	  significant	  difference	  (p<0.05)	  between	  the	  IgG	  control	  and	  the	  hnRNP	  K	  RIP.	  The	  data	  are	  the	  mean	  ±	  SE	  of	  n=3	  mice	  per	  group.	  (C)	  GAPDH	  mRNA	  immunoprecipitated	  by	  the	  hnRNP	  K	  antibody	  was	  measured	  by	  RT-­‐qPCR	  using	  primers	  to	  GAPDH	  (nt	  2281-­‐2348)	  in	  order	  to	  assess	  specificity	  of	  hnRNP	  K	  binding.	  Data	  are	  expressed	  as	  fold	  increase	  in	  enrichment	  relative	  to	  the	  amount	  of	  IgG	  enrichment.	  (D)	  Total	  RNA	  was	  isolated	  from	  a	  portion	  of	  liver	  used	  in	  the	  RIP	  analysis.	  G6PD	  mRNA	  was	  measured	  using	  RT-­‐qPCR	  as	  previously	  
 100 
described.	  The	  data	  are	  the	  mean	  ±	  SE	  of	  n=3	  mice	  per	  group.	  The	  “*”	  symbol	  indicates	  a	  significant	  difference	  (p<0.05).	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Appendix	  Experiment	  #1	  
The	  purpose	  of	  the	  experiment	  was	  to	  determine	  if	  the	  serine	  and/or	  tyrosine	  phosphorylation	  of	  hnRNP	  K	  changes	  due	  to	  nutrient	  signals.	  	  	  
	  





































phosphorylation	  of	  serine	  residues	  within	  hnRNP	  K.	  (B)	  A	  western	  blot	  after	  the	  immunoprecipitation	  of	  hnRNP	  K	  is	  shown	  that	  was	  blotted	  for	  phosphorylation	  of	  tyrosine	  residues	  within	  hnRNP	  K.	  	  The	  treatments	  did	  not	  alter	  the	  phosphorylation	  of	  hnRNP	  K.	  This	  data	  represents	  one	  time	  point	  and	  does	  not	  completely	  rule	  out	  that	  these	  nutrient	  signals	  do	  not	  alter	  the	  phosphorylation	  of	  hnRNP	  K.	  	  
Appendix	  Experiment	  #2	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Figure	  2.	  Depletion	  of	  hnRNP	  M	  by	  siRNA	  causes	  a	  slight	  but	  not	  significant	  decrease	  in	  the	  splicing	  of	  G6PD	  mRNA.	  HepG2	  cells	  stably	  expressing	  Exon	  12(+)were	  transfected	  with	  75nM	  siRNA	  against	  hnRNP	  M	  or	  a	  non-­‐targeting	  (NT)	  control.	  After	  48	  hours,	  RNA	  and	  protein	  were	  isolated.	  (A)	  A	  representative	  immunoblot	  of	  hnRNP	  M	  depletion	  in	  HepG2	  cells	  is	  shown.	  (B)	  Expression	  of	  mRNA	  produced	  by	  the	  Exon	  12(+)	  reporter	  in	  HepG2	  cells	  that	  were	  transfected	  with	  the	  indicated	  siRNA	  was	  measured	  with	  the	  primers	  to	  the	  β-­‐galactosidase	  sequence.	  The	  data	  are	  normalized	  to	  the	  amount	  of	  GAPDH	  mRNA.	  The	  data	  is	  expressed	  as	  fold	  change	  to	  the	  NT	  control.	  The	  data	  are	  the	  mean	  ±	  SE	  of	  n=5	  independent	  siRNA	  knockdowns.	  	  (C)	  Following	  knockdowns	  with	  the	  indicated	  siRNA,	  splicing	  of	  the	  reporter	  RNA	  was	  measured.	  The	  products	  of	  a	  representative	  RT-­‐PCR	  are	  shown.	  (D)	  Quantification	  of	  changes	  in	  the	  splicing	  ratio	  is	  calculated	  as	  the	  intensity	  of	  the	  spliced	  band	  over	  intensity	  of	  the	  band	  of	  unspliced	  RNA.	  The	  data	  represent	  the	  mean	  ±	  SE	  of	  n=5	  independent	  siRNA	  transfections.	  
The	  knockdown	  of	  hnRNP	  M	  has	  a	  trend	  toward	  the	  inhibition	  of	  splicing	  of	  the	  reporter	  mRNA	  and	  mRNA	  expression.	  The	  knockdown	  of	  hnRNP	  M	  has	  the	  opposite	  effect	  on	  reporter	  expression	  and	  splicing	  when	  compared	  to	  hnRNP	  K.	  It	  is	  possible	  that	  the	  effects	  of	  hnRNP	  M	  knockdown	  are	  indirect	  as	  the	  binding	  of	  hnRNP	  M	  to	  the	  regulatory	  element	  has	  not	  been	  detected.	  	  
 
 
